                               NBER WORKING PAPER SERIES




             IDENTIFYING SOURCES OF INEFFICIENCY IN HEALTH CARE

                                        Amitabh Chandra
                                        Douglas O. Staiger

                                       Working Paper 24035
                               http://www.nber.org/papers/w24035


                     NATIONAL BUREAU OF ECONOMIC RESEARCH
                              1050 Massachusetts Avenue
                                Cambridge, MA 02138
                         November 2017, Revised December 2019




This research was funded by the National Institute of Aging (NIA) P01 AG19783-02. We thank
Janet Currie, Joe Doyle, Mark Duggan, Amy Finkelstein, Peter Hull, Matt Notowidigdo, Jonathan
Skinner, and Heidi Williams and the editors and referees for comments that have greatly
improved our paper. We obtained access to the proprietary data used in this paper through a data
use agreement between the Centers for Medicare and Medicaid Services (CMS) and Dartmouth
Medical School. Readers wishing to use these data must obtain them from CMS, but programs
and output are available from the authors. The views expressed herein are those of the authors
and do not necessarily reflect the views of the National Bureau of Economic Research.

At least one co-author has disclosed a financial relationship of potential relevance for this
research. Further information is available online at http://www.nber.org/papers/w24035.ack

NBER working papers are circulated for discussion and comment purposes. They have not been
peer-reviewed or been subject to the review by the NBER Board of Directors that accompanies
official NBER publications.

Â© 2017 by Amitabh Chandra and Douglas O. Staiger. All rights reserved. Short sections of text,
not to exceed two paragraphs, may be quoted without explicit permission provided that full
credit, including Â© notice, is given to the source.
Identifying Sources of Inefficiency in Health Care
Amitabh Chandra and Douglas O. Staiger
NBER Working Paper No. 24035
November 2017, Revised December 2019
JEL No. I1,I3

                                          ABSTRACT

In medicine, the reasons for variation in treatment rates across hospitals serving similar patients
are not well understood. Some interpret this variation as unwarranted, and push standardization of
care as a way of reducing allocative inefficiency. An alternative interpretation is that hospitals
with greater expertise in a treatment use it more because of their comparative advantage,
suggesting that standardization is misguided. A simple economic model provides an empirical
framework to separate these explanations. Estimating this model with data for heart attack
patients, we find evidence of substantial variation across hospitals in both allocative inefficiency
and comparative advantage, with most hospitals overusing treatment in part because of incorrect
beliefs about their comparative advantage. A stylized welfare-calculation suggests that
eliminating allocative inefficiency would increase the total benefits from the treatment that we
study by 44%.


Amitabh Chandra
John F. Kennedy School of Government
Harvard University
79 JFK Street
Cambridge, MA 02138
and NBER
amitabh_chandra@harvard.edu

Douglas O. Staiger
Dartmouth College
Department of Economics
HB6106, 301 Rockefeller Hall
Hanover, NH 03755-3514
and NBER
douglas.staiger@dartmouth.edu
        A large and influential literature in economics and medicine has documented substantial
variation in treatment rates and patient outcomes across hospitals even after carefully controlling for
differences in patient risk [Skinner (2011); Institute of Medicine (2013)]. But this variation in treatment
rates could arise from two different mechanisms. The conventional interpretation in the medical
literature is that there is a correct amount of use, so that variation across providers in risk-adjusted
treatment rates is evidence of allocative inefficiency: some providers are using too much care and others
are using too little. This interpretation of variation has led to an emphasis on guidelines and developing
and disseminating information on cost-effectiveness of care. 1 A different interpretation is that the ability
to deliver treatment varies across providers, so that hospitals who can obtain higher benefits from a
given treatment deliver more of that treatment because of their comparative advantage. This
interpretation leads to an emphasis on understanding the sources of variation in hospital-specific skill
and efforts to improve quality, instead of trying to standardize care.
        We develop a simple economic framework that can distinguish between these explanations and
shed light on the mechanisms behind them. Our framework builds on a generalized Roy model of
treatment choice along the lines of Chandra and Staiger (2007), where treatment choice depends on the
expected benefits of treatment relative to usual care. In this model, differences across hospitals in risk-
adjusted treatment rates do not separately identify allocative inefficiency because they also capture
differences in comparative advantage across hospital in providing the treatment. However, if treatment
is being allocated efficiently to patients then any difference in the propensity to be treated, whether
across patients or across hospitals, should solely reflect differences in the expected benefit from the
treatment. Therefore, allocative inefficiency can be identified when the benefit of treatment is different
across hospitals for patients with the same propensity to be treated. Furthermore, since low propensity
patients are those least likely to benefit from treatment, overuse of the treatment in a given hospital can
be identified when the treatment does harm among patients with the lowest propensity to receive
treatment.
        We use rich clinical data from the Cooperative Cardiovascular Project for elderly patients
experiencing heart-attacks in the mid-1990s and being treated with reperfusion therapy to estimate
variation across patients and hospitals in both the propensity to be treated and treatment effects. Because
of the richness of the clinical variables in our data, we are able to credibly estimate treatment effects,


1
  There are many sources of guidelines and recommendations in healthcareâ€”ranging from screening guidelines
from the US Preventative Task Force (USPTF), to treatment guidelines from the American College of
Cardiology (Oâ€™Gara et al, 2013) for heart-attacks, to treatment guidelines for very specific cancers from the
American Society of Clinical Oncologists (Burstein et al, 2018).




                                                                                                                2
replicating estimates from randomized controlled trials and demonstrating robustness of our estimates
to controlling for increasingly detailed covariates. We find that aggressive hospitals (with high risk-
adjusted treatment rates) are much more likely to treat patients with negative treatment effects,
suggesting overuse of treatment in these hospitals.
        To interpret these results, we estimate the model implied by our economic framework and use
it to separately identify variation across hospitals in allocative inefficiency and comparative advantage.
While our model can be applied to any healthcare setting, heart-attack treatments have several features
that make them particularly suited for the analysis: outcomes are easily measured and agreed upon, and
questions about overuse, underuse and comparative-advantage are central to treatment decisions.
Estimating our model, we find strong evidence of allocative inefficiency, with most hospitals overusing
reperfusion therapy to the point that low propensity patients are harmed by the treatment. However, we
also find substantial variation in hospitalsâ€™ ability to perform treatment (comparative advantage), with
the variation across hospitals in the survival benefit from reperfusion being the same order of magnitude
as the average treatment effect of reperfusion. Thus, we find that both allocative inefficiency and
comparative advantage contribute to variations in treatment rates.
        We use this framework to explore mechanisms that could lead to the allocative inefficiency that
we observe in the data. One possibility, motivated by Currie and MacLeod (2017), is that allocative
inefficiency would arise if hospitals had imperfect information and misperceived their ability to deliver
treatment. In this mechanism, allocative inefficiency arises because hospitals base treatment decisions
on their incorrect perception of the benefits of treatment in their patients, rather than on the true benefits
of treatment. Given the general lack of systematic performance feedback and small samples of their own
treated patients to observe, it is quite plausible that hospitals and physicians will have inaccurate beliefs
about their own treatment effectiveness. We find evidence in favor of this mechanism, with smaller
hospitals having particularly imprecise information about their own treatment effectiveness. Another
explanation is that hospitals are optimizing something other than the survival of a given patient, e.g.
over-treating for financial gain (particularly in for-profit hospitals) or because of benefits to future
patients through learning-by-doing (particularly in teaching hospitals). This type of mechanism would
suggest that allocative inefficiency would be related to hospital characteristics such as ownership,
teaching status, etc. We find little prima facie evidence for this hypothesisâ€”overuse is not correlated
with a hospitalâ€™s for-profit status or other characteristics such as being a teaching-hospital.
        Our contribution connects the vast empirical literature on variations in medical care to the
broader economics literature on productivity and technology adoption. Most of the literature on
variations in medical care has ignored the role of productivity in driving variation in treatment, and




                                                                                                            3
instead debated whether finding variation in risk-adjusted treatment rates that is unrelated to patient
outcomes points to allocative inefficiency or is simply due to inadequate risk-adjustment [Fisher et al
(2003a, 2003b), Yasaitis (2009), Skinner (2011), Doyle (2011), Doyle, Graves, Gruber, Kleiner (2015),
Finkelstein, Gentzkow, Williams (2016)]. In contrast, research influenced by the productivity literature
(Syverson, 2011) has emphasized productivity differences in healthcare [Chandra and Staiger (2007),
Chandra et al (2016), Skinner and Staiger (2015), Currie and MacLeod (2017)], but ignored the
possibility of allocative inefficiency across hospitals. More specifically, evidence that comparative
advantage drives variation across firms in technology adoption has been found in agriculture (Suri,
2011) and in health care (Chandra and Staiger, 2007), but these papers do not account for allocative
inefficiency. Our paper is the first to separately identify variation due to comparative advantage from
that due to allocative inefficiency. We build on the framework used in Chandra and Staiger (2010), but
where that paper focused on differences in treatment rates across demographic groups this paper
focusses on differences across hospitals. Our contribution is closest to that of Abaluck et al. (2016), who
build on an earlier working-paper version of this paper. While they allow for allocative inefficiency and
physician level expertise in selecting patients for testing, we differ in allowing for comparative
advantage and productivity differences across hospitals in addition to differences in allocative
efficiency.
        The paper proceeds as follows: Section I provides some background on heart attack biology and
treatment, describes the data, and provides some motivating facts documenting how simple estimates of
treatment rates and treatment effects vary across hospitals and patients. Section II develops a theoretical
model for understanding these facts, and links it to our estimation strategy, paying particular attention
to how allocative inefficiency will be identified separately from comparative advantage and productivity
differences. Section III presents graphical results and regressions suggested by our theoretical model
which then motivate a more parametric approach. In Section IV we use our framework to understand
mechanisms and estimate a simple Bayesian learning model for learning comparative advantage and
compare its fit, relative to simpler stories about learning and financial-incentives. We conclude by
performing some stylized calculations of the welfare-loss from variation in treatment rates. All appendix
material can be found in an online appendix.


              I. HEART-ATTACKS: TREATMENTS, DATA, AND SOME MOTIVATING FACTS
I.A. Treatments
        Heart attacks (more precisely, acute myocardial infarction (AMI)) occur when the heart-muscle
(the myocardium) does not receive sufficient oxygen, because of a blockage in one of the coronary




                                                                                                         4
arteries which supply blood to the heart. The blockage is typically caused by a blood clot that occurs
because of coagulation induced by the rupture of atherosclerotic plaque inside the coronary arteries, and
must be reperfused rapidly. There are two ways to give patients reperfusion (which is the treatment that
we study): first, thrombolytics, also known as fibrinolytics, are administered intravenously and break
down blood clots by pharmacological means (these drugs include tissue plasminogen activators,
streptokinanse and urokinase). Not everyone is appropriate for thrombolyticsâ€”patients with strokes,
peptic ulcers, head-trauma, dementia, advanced liver disease, and uncontrolled hypertension arenâ€™t
appropriate for this treatment because of the risk of further bleeding induced by the treatment.
Reperfusion can also be performed through angioplasty (where a balloon on a catheter is inflated inside
the blocked coronary artery to restore blood flow). Following the clinical literature, we define a patient
to have received reperfusion if any of these therapies was provided within 12 hours of the heart attack.
In our data from the mid-1990s, over 90 percent of patients receiving reperfusion received
thrombolytics.
        We focus our empirical work on the treatment of AMI for a number of reasons. First,
cardiovascular disease, of which heart attacks are the primary manifestation, is the leading cause of
death in the US. A perusal of the leading medical journals would indicate that heart attack treatments
are constantly being refined, and a large body of trial evidence points to significant therapeutic gains
from many of these treatments. In this context, variation in treatments across hospitals may directly
translate into lost lives, and there is a rich tradition of studying variation across hospitals in treatments
and outcomes after heart attacks.
        Second, because of what is known about heart attack treatments from randomized controlled
trials, we are able to assess whether our regression estimates of the benefits from reperfusion are
comparable to those found in the medical literature, or whether they are confounded by selection-bias.
We focus on reperfusion, where our use of chart data allows us to replicate the RCT evidence that is
summarized by the Fibrinolytic Therapy Trialists' Collaborative Group (1994). Chart data provides
comprehensive documentation on the patientâ€™s condition at the time that the treatment decision is made,
and therefore minimizes the possibility that unobserved clinical factors related to a patientâ€™s survival are
correlated with treatment.
         Third, because mortality post-AMI is high (mortality rates at 30 days are nearly 20 percent), a
well-defined endpoint is available to test the efficacy of heart attack treatments. Moreover during the
acute phase of the heart attack the therapeutic emphasis is on maximizing survival, which is achieved
by timely reperfusion, and hospital staff (not patients and their families) make treatment decisions. This
would not be true if we focused on treatment variation for more chronic conditions such as diabetes,




                                                                                                           5
chronic obstructive pulmonary disease, or arthritis where because of the importance of quality-of-life
there would be considerable disagreement on how to measure productivity.
         Fourth, heart attacks are an acute condition for which virtually all patients are hospitalized at a
nearby hospital and receive some medical care. This may not be true of more chronic conditions such
as diabetes or heart-failure where many patients arenâ€™t diagnosed and selection confounds the analysis.
         Fifth, within hospitals, heart-attacks are treated by teams comprising doctors and nurses in the
emergency room, in the hospital, in cardiac-care units and in post-acute facilities. This makes heart-
attacks treatments more hospital-oriented than other areas of medicine where an individual physician
may have a primary role. This motivates our focus on hospitals over individual physicians. 2 Most
relevant to our paper, we donâ€™t have physician or team identifiers in our data. Nor do the data that we
have, or most other claims data, identify the first physician who saw the patient in the emergency-room
(this is key for attribution because all subsequent physicians are endogenous to this first physician).
Even if we had these identifiers, weâ€™d need assignment to subsequent physicians to be random. While
this is possibly true for emergency-room physicians, itâ€™s unlikely to be true for other downstream
physicians.


I.B. Data
         Because acute myocardial infarction is both common and serious, it has been the topic of intense
scientific and clinical interest. One effort to incorporate evidence-based practice guidelines into the care
of heart attack patients, begun in 1992, is the Health Care Financing Administration's Health Care
Quality Improvement Initiative Cooperative Cardiovascular Project (CCP). The CCP samples all
Medicare beneficiaries who had an heart-attack between February 1994 and July 1995 (45 states),
between August and November, 1995 for Alabama, Connecticut, Iowa, and Wisconsin, and between
April and November 1995 (Minnesota). The CCP used bills submitted by acute care hospitals and
contained in the Medicare claims to identify all Medicare discharges with a principal diagnosis of
myocardial infarction. These data were matched to hospital clinical records. The CCP is considerably
superior to administrative/claims data of the type used by McClellan et al. (1994) as it collects chart data


2
  We also note that the medical literature around measuring individual physician quality, does not examine the
quality of physicians for heart-attack treatments. The literature on physician-level measures typically looks at
high-mortality and common conditions such as carotid endarterectomy, coronary artery bypass grafting, valve
replacement, abdominal aortic aneurysm repair, lung resection, cystectomy, pancreatic resection, and
esophagectomy. Heart-attacks are common and high-mortality, so our sense for why the medical literature has
not looked at physician quality in this setting is that it is hard to do and may not be key relative to hospital-level
factors.




                                                                                                                         6
on the patientsâ€”detailed information is provided on laboratory tests, enzyme levels, the location of the
myocardial infarction, and the condition of the patient at the time of admission. Detailed clinical data
were abstracted from each patientâ€™s chart using a standard protocol. Further details about the CCP data
are available in Marciniak et al. (1998), Oâ€™Connor et al. (1999), and in Appendix I. The choice of sample
and variables is identical to what we used and described in Barnato et al. (2005) and Chandra and Staiger
(2007, 2010).
           One concern with using the CCP is that data from the mid-1990s may be less relevant today:
perhaps variations have fallen, or perhaps variations today arenâ€™t reflective of variations from many
years ago. 3 To explore whether variation from the 1990s is similar to variation in more recent years, we
used Medicare fee-for-service data and examined a sample of 2,970 hospitals that treated heart-attacks
in Medicare in 1992-5 and in 2012-15. We dropped hospitals that closed or merged or opened in this
window. Since reperfusion is not recorded in claims data, we instead used cardiac-catheterization as a
proxy for intensive management (Chandra and Staiger, 2007). 4 Over this time period, cardiac-
catheterization rates for heart-attack patients increased from 35% to 52%. Over twenty years, the
correlation between hospital-level catheterization rates is 0.69 (unweighted) and 0.73 (patient weighted),
showing that treatment intensity is highly correlated over time. In both periods, the standard-deviation
of these hospital-level treatment rates was about the same: 0.23 and 0.25 respectively, suggesting that
hospital variations continue to be a persistent phenomenon.
           We report some basic characteristics of our sample in Table I. In our sample, 19% of patients
received reperfusion within 12 hours of admission for a heart attack. Overall, 81% of patients were still
alive 30 days after admission, but survival was higher for patients receiving reperfusion (86%) than for
patients who did not receive reperfusion (80%). However, much of the difference in survival between
these two groups may be due to differences in underlying health and pre-existing conditions, rather than
the result of reperfusion. Overall, patients in the sample are elderly (average age of 76.7) and have high
rates of chronic conditions such as hyptertension (62%), diabetes (30%) and congestive heart failure



3
  Chandra and Skinner (2012) argue that the scope of allocative inefficiency has increased over time because
new medical technologies have fewer side-effects (e.g. stents and many pharmaceutical treatments) and that
increases the scope for overusing them, in the sense of using a technology whose marginal benefit is less than its
social cost. In the past, technologies were more invasive or had larger side-effects (for example cardiac bypass),
and that reduced the willingness to overuse them because death may have been an immediate side-effect of using
invasive procedures in marginally less appropriate patients. We are less sure about whether the scope for
comparative advantage differences is increasing over time, but to the extent that more complicated medicine
requires more expertise in how different inputs are combined, then the answer to this may be affirmative as well.
4
    In the CCP data, reperfusion and catheterization are correlated 0.35 at the hospital level.




                                                                                                                 7
(22%). However, patients receiving reperfusion were relatively younger, and much less likely to have
these pre-existing conditions.
        We have 4690 hospitals in the sample. Patients receiving reperfusion were treated in similar
hospitals in terms of ownership, teaching status, and size of the hospital, reflecting the fact that
reperfusion is a procedure that does not require special hospital capabilities and is done in nearly all
hospitals. The average hospital in our sample has 30 patients, with 10th percentile hospital serving fewer
than 11 patients and 90th percentile hospital having 73 patients. The average patient is in a hospital with
67 patients and the 10th percentile patient is in a hospital with 15 patients and the 90th percentile patient
is in a hospital with 133 patients.


I.C. Motivating Facts
        We begin by documenting some key empirical facts about how treatment rates and treatment
effects vary across hospitals and across patients. This model-free summary of key facts motivates the
theoretical and empirical model that we develop below and use to interpret this variation. To describe
variation in treatment rates we use the CCP sample (Table I) to estimate a random-effect logit model of
whether a patient received reperfusion within 12 hours regressed on a rich set of covariates derived from
patient charts (see Appendix I for a full list) and a hospital-level random intercept. We use empirical
Bayes (shrinkage) estimates of the random logit intercepts to capture variation in treatment rates at the
hospital level for observationally similar patients, and use the estimated treatment propensity index
based on patient covariates (without the hospital intercept) to capture variation in treatment rates at the
patient level. Empirical Bayes estimates account for estimation error due to small samples of patients in
each hospital, and tend to understate the true amount of variation in the hospital-level parameters. To
describe variation in the effect of reperfusion on survival we estimate a random-coefficient logit model
of whether a patient survived 30 days after their heart attack regressed on whether the patient received
reperfusion within 12 hours, controlling for the full set of patient covariates, and allowing for a hospital-
level random intercept and (possibly correlated) random coefficient on reperfusion. We again use
empirical Bayes estimates of the random coefficient on reperfusion to capture variation in the treatment
effect at the hospital level. As we discuss in more detail below, this survival logit estimates an average
effect of reperfusion that is very similar to estimates from randomized controlled trials, suggesting that
the CCP control variables are sufficient to yield unbiased estimates of the treatment effect.
        Panel A of Figure I illustrates how treatment rates and treatment effects vary across hospitals.
For each of our 4690 hospitals, we plot the hospital intercept estimated from the reperfusion logit (x
axis) versus the hospital treatment effect estimated from the survival logit (y axis). This figure illustrates




                                                                                                            8
three key facts. First, there is large variation across hospitals in risk-adjusted treatment rates (the
reperfusion intercepts), ranging from -1 to 1 (in logodds, where an average hospital is normed to 0). This
fact is at the heart of the variations literature in economics and medicine, and has led some to argue that
uniform treatment guidelines are needed to reduce unwarranted variation. Second, there is also
substantial variation across hospitals in the benefit from treatment (the treatment effect from the survival
logit), ranging from slightly negative (indicating harm) to a positive effect on the logodds of survival of
over 0.4. This fact is fairly novel, 5 and challenges the notion of uniform treatment guidelines which
implicitly assume that there is no hospital-level variation in the benefit from treatment. The third fact is
that these hospital level treatment rates and treatment benefits are uncorrelated (correlation = -.02). This
fact raises a puzzleâ€”why are hospitals with a low benefit from treatment treating patients at the same
rate as hospitals with a high benefit from treatment? One answer may be overuse.
         Panel B of Figure I illustrates how treatment rates vary across patients. In Panel B, we non-
parametrically plot the probability of treatment as a function of the treatment propensity index from the
reperfusion logit based on patient covariates (without the hospital intercept), estimating separate lines
for the probability of treatment in hospitals in the highest (most aggressive) and lowest (most
conservative) terciles of risk-adjusted treatment rates (the hospital-level reperfusion intercept). This
figure illustrates two additional facts. First, treatment increases with the propensity index for both types
of hospitals. This suggests that both aggressive and conservative hospitals use patient characteristics
similarly to sort patients into more or less appropriate for treatment. Second, the line for hospitals in the
highest tercile is both higher and extends further to the left. This underscores the point that hospitals
with higher risk-adjusted treatment rates are going much deeper into the distribution of observable
patient characteristics.
         Panel C of Figure I illustrates how the survival benefits of reperfusion (the treatment effects)
vary across patients. Similarly to Panel B, Panel C non-parametrically plots the treatment effect as a
function of the treatment propensity index based on patient characteristics, separately for hospitals in
the highest (most aggressive) and lowest (most conservative) terciles of risk-adjusted treatment rates.
The survival benefit at each point in the distribution of the propensity index was estimated flexibly using
a local-logistic regression of 30-day survival on reperfusion that controlled for the detailed risk adjusters
available in the CCP. This figure illustrates three final facts. First, for both types of hospitals, the benefit
associated with reperfusion is increasing with the propensity index. This suggests that patients with



5
  Hospital-level variation in patient outcomes (and their relationship to treatment rates) is well documented in the
literature, but few studies have tried to estimate hospital-level variation in the return to treatment (Skinner,
2011).



                                                                                                                  9
greater benefits from treatment are more likely to receive treatment and, conversely, that the treatment
propensity serves as a strong indicator of a patientâ€™s expected benefit from treatment. Thus, while
treatment rates are uncorrelated with treatment effects at the hospital level, they are strongly correlated
at the patient level. The second fact is that reperfusion is associated with worse survival (indicating
harm) for patients with low treatment propensity, particularly for patients treated in aggressive hospitals
with high risk-adjusted treatment rates. The aggressive hospitals treat between 10 and 30 percent of
patients for whom we estimate reperfusion is associated with worse survival, while the conservative
hospitals treat fewer than 10 percent of these patients. This evidence suggests that aggressive hospitals
are over-treating some patients. Finally, it is interesting to note that the benefit associated with
reperfusion for patients with the same characteristics are about the same despite the 30 point higher
probability of being treated in the higher tercile hospitals. If top tercile hospitals treated more patients
because of comparative advantage (greater benefit from reperfusion in these hospitals), we would expect
higher benefits associated with reperfusion in these hospitals. If anything, we observe lower returns in
the aggressive hospitals among low propensity patients. This fact, along with observing negative
benefits among the lower propensity patients, suggests the existence of allocative inefficiency.


                                      II. THEORY AND ESTIMATION
        A Roy model of patient treatment choice guides our empirical work. We assume that a hospital
must choose between two treatment options for every patient: whether to offer reperfusion (treatment)
or not (usual care). Treatment is provided to each patient whenever a patientâ€™s expected benefit from the
treatment exceeds a minimal threshold. In our framework, there are two ways in which a patientâ€™s
hospital could affect treatment. First, because of comparative-advantage, the benefit of treatment for a
given patient may vary across hospitals, reflecting each hospitalâ€™s expertise in providing the treatment.
Second, because of allocative efficiency, the minimum threshold for receiving care may vary across
hospitals. From the patientâ€™s point of view, treatment should be provided whenever the expected benefit
from treatment exceeds zero. Therefore, there is underuse of the treatment in hospitals that set a
minimum benefit threshold above zero, and overuse in hospitals that set a minimum threshold below
zero.
II.A. Patient Outcomes
                                  1
        To formalize this, let ğ‘Œğ‘Œğ‘–ğ‘–â„ represent the survival for patient i at hospital h if the patient receives
the treatment (reperfusion) and let ğ‘Œğ‘Œğ‘–ğ‘–â„0 represent the survival if the patient does not receive the treatment,




                                                                                                             10
but otherwise receives usual medical care. 6 We focus on the health benefits of the treatment, which in
our setting is survival, but in other settings would include any reduction in mortality or morbidity that
was expected from the treatment, e.g. the impact of the treatment on Quality Adjusted Live Years
(QALYs). 7 Treatment decisions are based on expected survival given the information available to the
provider at the time of treatment. If receiving usual care, a patientâ€™s expected survival ğ¸ğ¸ï¿½ğ‘Œğ‘Œğ‘–ğ‘–â„0 ï¿½ depends
on the hospitalâ€™s general level of expertise ğ›¼ğ›¼â„0 , observable patient characteristics Xih such as age, medical
                                                                                      0
history and lab results, and other unmeasured factors affecting baseline mortality ğ‘£ğ‘£ğ‘–ğ‘–â„ that are observed
by the healthcare provider but not by the econometrician. If treated with reperfusion, a patientâ€™s expected
               1
survival ğ¸ğ¸ï¿½ğ‘Œğ‘Œğ‘–ğ‘–â„ ï¿½ depends on a similar set of factors representing the hospitalâ€™s expertise at providing the
treatment ğ›¼ğ›¼â„1 , patient characteristics (which may have a different relationship to survival when patients
                                                       1
receive the treatment), and other unmeasured factors ğ‘£ğ‘£ğ‘–ğ‘–â„ that affect the expected benefits of reperfusion.
The presence of two productivity parameters ğ›¼ğ›¼â„1 and ğ›¼ğ›¼â„0 , allows us to model hospital specific benefits at
both forms of medicineâ€” usual care and reperfusion (treatment).
         Actual (realized) survival if receiving usual care or reperfusion is equal to expected survival
                             0      1
plus a random error term (ğœ€ğœ€ğ‘–ğ‘–â„ , ğœ€ğœ€ğ‘–ğ‘–â„ ), which yields survival equations of the following form:

(1a)     ğ‘Œğ‘Œğ‘–ğ‘–â„0 = ğ¸ğ¸ï¿½ğ‘Œğ‘Œğ‘–ğ‘–â„0 ï¿½ + ğœ€ğœ€ğ‘–ğ‘–â„
                                   0                          0
                                      = ğ›¼ğ›¼â„0 + ğ‘‹ğ‘‹ğ‘–ğ‘– ğ›½ğ›½â„0 + ğ‘£ğ‘£ğ‘–ğ‘–â„      0
                                                                 + ğœ€ğœ€ğ‘–ğ‘–â„
            1          1        1                          1       1
(1b)     ğ‘Œğ‘Œğ‘–ğ‘–â„ = ğ¸ğ¸ï¿½ğ‘Œğ‘Œğ‘–ğ‘–â„ ï¿½ + ğœ€ğœ€ğ‘–ğ‘–â„ = ğ›¼ğ›¼â„1 + ğ‘‹ğ‘‹ğ‘–ğ‘– ğ›½ğ›½â„1 + ğ‘£ğ‘£ğ‘–ğ‘–â„ + ğœ€ğœ€ğ‘–ğ‘–â„
                                                                                                           âˆ†
The benefit, or gain, or return, from reperfusion treatment for patient i in hospital h is Yih given by:

(1c)     ğ‘Œğ‘Œğ‘–ğ‘–â„Î” = ğ›¼ğ›¼â„Î” + ğ‘‹ğ‘‹ğ‘–ğ‘– ğ›½ğ›½ Î” + ğ‘£ğ‘£ğ‘–ğ‘–â„
                                        Î”       Î”
                                           + ğœ€ğœ€ğ‘–ğ‘–â„ ,
                                                            Î”      1        0         Î”      1        0
         where ğ›¼ğ›¼â„Î” = ğ›¼ğ›¼â„1 âˆ’ ğ›¼ğ›¼â„0 , ğ›½ğ›½â„âˆ† = ğ›½ğ›½â„1 âˆ’ ğ›½ğ›½â„0 , ğ‘£ğ‘£ğ‘–ğ‘–â„ = ğ‘£ğ‘£ğ‘–ğ‘–â„ âˆ’ ğ‘£ğ‘£ğ‘–ğ‘–â„ and ğœ€ğœ€ğ‘–ğ‘–â„ = ğœ€ğœ€ğ‘–ğ‘–â„ âˆ’ ğœ€ğœ€ğ‘–ğ‘–â„
Similarly, the expected benefit from reperfusion at the time of choosing treatment is given by:
(1d)     ğ¸ğ¸ï¿½ğ‘Œğ‘Œğ‘–ğ‘–â„Î” ï¿½ = ğ›¼ğ›¼â„Î” + ğ‘‹ğ‘‹ğ‘–ğ‘– ğ›½ğ›½â„âˆ† + ğ‘£ğ‘£ğ‘–ğ‘–â„
                                             Î”


In Equation (1d), ğ›¼ğ›¼â„Î” represents the hospital-specific benefit in providing reperfusion. One could think
of ğ›¼ğ›¼â„0 as representing a hospitalâ€™s Total Factor Productivity (TFP)â€” because increases in it reflect
improvements that are unrelated to specific treatments such as reperfusion or surgery [Garber and


6
  Throughout this section we treat survival, Y, as a continuous outcome measure. In the empirical work, we use
binary outcomes indicating whether the patient survived beyond 30 days (or other thresholds). Thus, Y is the
latent variable in the survival logits that we estimate.
7
  For now, we abstract from the problem that hospitals should also think about costs and stop treatment prior to
achieving zero marginal benefitsâ€”that is, that maximize benefits net of cost. We visit this issue in Section III.B.
The cost of treating heart-attacks is small relative to the survival benefit of the treatments, but this may not be
true for other medical conditions.



                                                                                                                 11
Skinner (2012) and Syverson (2001)]. Efforts to increase ğ›¼ğ›¼â„0 are efforts to increase productive
efficiency-- increasing the fraction receiving beta-blockers or improving patient safety are examples.
The higher the ğ›¼ğ›¼â„0 , the lower the benefit from reperfusion, for a fixed level of ğ›¼ğ›¼â„1 . Because ğ›¼ğ›¼â„Î” represents
the difference between the ability to perform reperfusion and usual care, we call it comparative-
advantage at reperfusion. Hospitals may have comparative advantage in providing reperfusion because
of either being particularly good at reperfusion treatment or being particularly bad at usual care for
patients. In the above equations, we have also allowed for hospital-level variation in how patient
characteristics affect outcomes through the ğ›½ğ›½â„âˆ† term, although in the empirical work we found these to
be unnecessary and assumed ğ›½ğ›½â„âˆ† = ğ›½ğ›½ âˆ† .
II.B. Treatment Choice
        Each patient receives treatment if the expected benefit from treatment exceeds a minimal
threshold Ï„h, where the threshold may vary across hospitals due to incentives or information as discussed
further below. Since ğ¸ğ¸ï¿½ğ‘Œğ‘Œğ‘–ğ‘–â„Î” ï¿½ captures the total expected benefit to the patient of providing treatment,
then the optimal decision from the patientâ€™s perspective would let Ï„h=0 and provide treatment whenever
the expected benefits to the patient exceed zero. There is underuse if Ï„ h > 0 , since patients with positive

benefits are under the threshold and do not receive treatment. There is overuse if Ï„ h < 0 , since patients

with negative benefits (who would do better without treatment) are above the threshold and receive
treatment.
        Figure 2A illustrates the intuition behind a Roy model of treatment at the hospital level. The
two lines denote patient survival if a hospital treats a given patient with usual care (intercept is ğ›¼ğ›¼â„0 ) or
using reperfusion (intercept is ğ›¼ğ›¼â„1 ) as a function of patient characteristics (i.e. patient Xâ€™s) on the x-axis.
                                                                                 Î”
To simplify exposition, we have suppressed the distribution of unobservables (ğ‘£ğ‘£ğ‘–ğ‘–â„ ). In reality, as well
as in our model and empirical work, providers observe these unmeasured characteristics and use them
to determine treatment. Expertise at usual care and reperfusion is captured by the intercepts ğ›¼ğ›¼â„0 and ğ›¼ğ›¼â„1
respectively, with comparative advantage being the difference between them.              Allocative efficiency
means that reperfusion should be performed to the point that the marginal patient receives zero benefit,
(Ï„h = 0), so that everyone to the right of the point of intersection should be treated and to the left should
receive usual care.
        First, consider the role of comparative-advantage in explaining treatment rates: ceteris paribus,
a hospital that is better at reperfusion would have a higher intercept for reperfusion ğ›¼ğ›¼â„1 , which would
increase the fraction of patients receiving reperfusion at that hospital. A hospital may also have a relative
advantage at reperfusion because it is worse at usual care. Either would increase ğ›¼ğ›¼â„Î” = ğ›¼ğ›¼â„1 âˆ’ ğ›¼ğ›¼â„0 and also



                                                                                                              12
increase the fraction of all patients being reperfused. Next, consider allocative inefficiency by a hospital
that over-treats patients with reperfusion therapy, and treats patients to the left of point of intersection.
This harms patients and lowers the average benefit from reperfusion amongst all patients receiving
reperfusion. Overuse is equivalent to setting Ï„h < 0, where some patients with negative benefits (harm)
are treated. Underuse of reperfusion happens when patients who are appropriate for reperfusion (to the
right of the intersection of the two lines) donâ€™t receive itâ€”a possibility that increases the benefits of
reperfusion amongst patients receiving it.
        This figure provides four pieces of intuition. First, knowledge of comparative-advantage doesnâ€™t
tell us where it originates fromâ€”it could arise from low ğ›¼ğ›¼â„0 , a high ğ›¼ğ›¼â„1 , or both. Second, allocative
inefficiency may arise from overuse Ï„ h < 0 (a willingness to perform reperfusion even if the benefit is

negative) or underuse Ï„ h > 0 (an unwillingness to perform reperfusion even when the benefit is

positive). Third, how a patient is treated depends on patient characteristics, the hospitalâ€™s comparative
advantage at delivering reperfusion (ğ›¼ğ›¼â„Î” ), and the level of allocative efficiency at the hospital (ğœğœâ„ ): all
three determine the propensity to be reperfused for a given patient at a given hospital. This brings us to
the fourth insight: variation across hospitals in treatment rates does not imply anything about the
presence of comparative-advantage versus allocative efficiency. Risk-adjusted hospital treatment rates
capture both mechanismsâ€”high risk-adjusted rates may arise because of high levels of hospital-specific
benefits at performing the treatment or a very low threshold for performing the treatment-- and do not,
by themselves, isolate the source of variation even with perfect risk-adjustment.
        Allocative inefficiency (ğœğœâ„ â‰  0) could come from a variety of sources. Figure 2B illustrates
how a hospital that misperceives its comparative-advantage from reperfusion and believes it to be higher
than it is, through overconfidence or imperfect knowledge about its comparative advantage, would
overuse reperfusion. It could also be that a hospital overuses reperfusion because it is maximizing
something other than health. These are alternative mechanisms that we explore in Section IV (we find
evidence for the misperception mechanism). Regardless of the mechanism for allocative inefficiency,
they cause a welfare loss whose magnitude is illustrated by the area of the triangle in the figure. The
height of the triangle is the threshold, and the base is the threshold multiplied by how much the threshold
increases the probability of receiving reperfusion. At the end of the paper, we aggregate the area of these
triangles to estimate the welfare loss from allocative inefficiency.
        We now specify our model of treatment choice more completely, paying particular attention to
how one can identify the different sources of inefficiency. The probability of receiving treatment is the
probability that expected benefits exceed the minimum threshold:




                                                                                                            13
(2)       Pr(ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘–ğ‘–â„ = 1) = Prï¿½ğ¸ğ¸ï¿½ğ‘Œğ‘Œğ‘–ğ‘–â„Î” ï¿½ > ğœğœâ„ ï¿½ = Prï¿½ğ›¼ğ›¼â„Î” + ğ‘‹ğ‘‹ğ‘–ğ‘– ğ›½ğ›½ Î” + ğ‘£ğ‘£ğ‘–ğ‘–â„
                                                                                            Î”                   Î”
                                                                                               > ğœğœâ„ ï¿½ = Prï¿½âˆ’ğ‘£ğ‘£ğ‘–ğ‘–â„ < ğ¼ğ¼ğ‘–ğ‘–â„ ï¿½,
            ğ‘¤ğ‘¤â„ğ‘’ğ‘’ğ‘’ğ‘’ğ‘’ğ‘’ ğ¼ğ¼ğ‘–ğ‘–â„ = ğ‘‹ğ‘‹ğ‘–ğ‘– ğ›½ğ›½ Î” + ğœƒğœƒâ„ ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ ğœƒğœƒâ„ = ğ›¼ğ›¼â„Î” âˆ’ ğœğœâ„
          In the terminology of Heckman, Urzua and Vytlacil (2006), our model allows for essential
heterogeneity where the decision to provide treatment to each patient is made with knowledge of their
                                        Î”
idiosyncratic response to treatment (ğ‘£ğ‘£ğ‘–ğ‘–â„ ). If we make the standard assumption that the distribution of
                                      Î”
patient-level idiosyncratic gains (ğ‘£ğ‘£ğ‘–ğ‘–â„ ) are i.i.d. (an assumption we return to below), then the parameters
(ğ›½ğ›½ Î” , ğœƒğœƒâ„ ) of Equation (2) can be estimated (up to scale) with a single index model such as a logit or OLS
regression of treatment on patient characteristics and hospital effects. 8 The hospital-specific intercept
(ğœƒğœƒâ„ ) in this equation is commonly referred to as the hospitalâ€™s risk-adjusted reperfusion rate, with higher
values indicating a more aggressive hospital where identical patients are more likely to receive
reperfusion. The hospital effect is ğœƒğœƒâ„ = ğ›¼ğ›¼â„Î” âˆ’ ğœğœâ„ , which means that a hospital may be more likely to

provide treatment because of greater comparative advantage at delivering treatment (                                            ), or

because of using a lower benefit threshold for providing care (Ï„ h < 0 ) reflecting overuse. Even if

treatment rates were the same across hospitals, there could still be overuse or underuse if, say, hospitals
with greater comparative advantage set a correspondingly higher threshold for providing care. Thus,
because variation in treatment rates across hospitals confounds variation in hospital comparative
advantage with hospital treatment thresholds, such variation cannot by itself say anything about overuse
or underuse.


II.C. Identifying Allocative Inefficiency
          We now demonstrate that allocative efficiency can be identified separately from comparative-
advantage if we can estimate the treatment effect for those patients receiving treatment. The treatment-
on-the-treated parameter is the average gain from treatment amongst those who were given treatment,

and can be obtained by conditioning the expression for                         (equation 1c) on the condition for receiving

treatment (equation 2):
(3)       ğ¸ğ¸ï¿½ğ‘Œğ‘Œğ‘–ğ‘–â„Î” |ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘–ğ‘–â„ = 1ï¿½ = ğ¸ğ¸ï¿½ğ‘Œğ‘Œğ‘–ğ‘–â„Î” |âˆ’ğ‘£ğ‘£ğ‘–ğ‘–â„
                                                                 Î”                                       Î”
                                                                    < ğ¼ğ¼ğ‘–ğ‘–â„ ï¿½ = ğ‘‹ğ‘‹ğ‘–ğ‘– ğ›½ğ›½ Î” + ğ›¼ğ›¼â„Î” + ğ¸ğ¸ï¿½ğ‘£ğ‘£ğ‘–ğ‘–â„      Î”
                                                                                                            |âˆ’ğ‘£ğ‘£ğ‘–ğ‘–â„ < ğ¼ğ¼ğ‘–ğ‘–â„ ï¿½
Noting that ğ‘‹ğ‘‹ğ‘–ğ‘– ğ›½ğ›½ Î” + ğ›¼ğ›¼â„Î” = ğ¼ğ¼ğ‘–ğ‘–â„ + ğœğœâ„ , we can rewrite Equation (3) as:
(4)       ğ¸ğ¸ï¿½ğ‘Œğ‘Œğ‘–ğ‘–â„Î” |ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘–ğ‘–â„ = 1ï¿½ = ğœğœâ„ + ğ‘”ğ‘”(ğ¼ğ¼ğ‘–ğ‘–â„ )


8
  Technically, logit models estimate ğ¼ğ¼ğ‘–ğ‘–â„ = (ğ‘‹ğ‘‹ğ‘–ğ‘– ğ›½ğ›½ Î” + ğœƒğœƒâ„ )/ğœğœğ‘£ğ‘£ where ğœğœğ‘£ğ‘£ is the standard deviation of the patient-level
                       Î”
idiosyncratic gains (ğ‘£ğ‘£ğ‘–ğ‘–â„ ). For now, we make the standard assumption that ğœğœğ‘£ğ‘£ =1. Most of the results in the paper
are invariant to the scale of ğ¼ğ¼ğ‘–ğ‘–â„ , but we will return to this point in the results section when we try to recover
estimates of ğ›¼ğ›¼â„âˆ† .



                                                                                                                                  14
                                          Î”       Î”
         where ğ‘”ğ‘”(ğ¼ğ¼ğ‘–ğ‘–â„ ) = ğ¼ğ¼ğ‘–ğ‘–â„ + ğ¸ğ¸ï¿½ğ‘£ğ‘£ğ‘–ğ‘–â„ |âˆ’ğ‘£ğ‘£ğ‘–ğ‘–â„ < ğ¼ğ¼ğ‘–ğ‘–â„ ï¿½
Here, g(I) is an unknown function of the propensity to receive treatment and the conditional expectation
      Î”       Î”                                                                                         Î”
ğ¸ğ¸ï¿½ğ‘£ğ‘£ğ‘–ğ‘–â„ ï¿½âˆ’ğ‘£ğ‘£ğ‘–ğ‘–â„ < ğ¼ğ¼ğ‘–ğ‘–â„ ï¿½. If we assume that the distribution of patient-level idiosyncratic gains (ğ‘£ğ‘£ğ‘–ğ‘–â„ ) are the
same for all patients and hospitals, then this conditional expectation is only a function of the index,
which means that g(ğ¼ğ¼ğ‘–ğ‘–â„ ) is only a function of ğ¼ğ¼ğ‘–ğ‘–â„ . This is an important assumption because our empirical
work relies heavily on the single-index property. The assumption would be violated, for example, if the
                                                                  Î”
variance or distribution of patient level idiosyncratic gains (ğ‘£ğ‘£ğ‘–ğ‘–â„ ) differed across hospitals. It is not
possible to test the single-index assumption by looking at differences in treatment on the treated by type
of hospital (for example, by hospital volume, size, non-profit status) because in our framework these
differences, conditional on propensity, reflect differences in thresholds. Because this is a key assumption
in our model, we will discuss supporting evidence for it in the empirical work. In particular, if the
variance of idiosyncratic gains differed across hospitals then we would also expect differences across
hospitals in the coefficients on patient characteristics in Equation 2 (predicting treatment). We will
                                                                                                Î”       Î”
explore this possibility later, but do not find this to be the case. The conditional mean ğ¸ğ¸ï¿½ğ‘£ğ‘£ğ‘–ğ‘–â„ ï¿½âˆ’ğ‘£ğ‘£ğ‘–ğ‘–â„ < ğ¼ğ¼ğ‘–ğ‘–â„ ï¿½
can also be modeled parametrically as a Mills-Ratio and we find support for this assumption as well.
         Equation (4) is the key result of the model that allows us to identify allocative inefficiency.
Equation (4) states that after conditioning on patient propensity to receive treatment, differences across
hospitals in the treatment effect on the treated are due solely to differences in the hospitalâ€™s minimum
threshold to deliver care (Ï„h). Note that the propensity to receive treatment (ğ¼ğ¼ğ‘–ğ‘–â„ ) depends on the hospital
effect (ğœƒğœƒâ„ ) and that includes both the presence of comparative advantage and allocative efficiency. By
conditioning on this propensity and examining differences in benefit across hospitals, we can isolate
differences in hospital thresholds. The intuition for this result is straightforward. By conditioning on the
propensity to receive treatment (ğ¼ğ¼ğ‘–ğ‘–â„ = ğ‘‹ğ‘‹ğ‘–ğ‘– ğ›½ğ›½ Î” + ğ›¼ğ›¼â„Î” âˆ’ ğœğœâ„ ), we hold the difference between the mean of
the benefit distribution (ğ‘‹ğ‘‹ğ‘–ğ‘– ğ›½ğ›½ Î” + ğ›¼ğ›¼â„Î” ) and the truncation threshold (ğœğœâ„ ) fixed. Thus, holding ğ¼ğ¼ğ‘–ğ‘–â„ constant,
any difference in ğœğœâ„ shifts both the mean of the benefit distribution and the truncation point by the same
amount (keeping the difference fixed), and therefore the truncated mean also increases by that same
amount. Had we not conditioned on the propensity (or just conditioned on ğ‘‹ğ‘‹ğ‘–ğ‘– ğ›½ğ›½ Î” as we did for the
motivating facts in Figure I), differences across hospitals in the treatment effect on the treated would be
difficult to interpret because they would depend on both comparative advantage (ğ›¼ğ›¼â„Î” ) and allocative
inefficiency (ğœğœâ„ ).
         Note that our model does not, by itself, uncover mechanisms for overuse or underuseâ€”we will
investigate these later. It is possible that overuse occurs because providers are worried about malpractice,




                                                                                                                  15
because theyâ€™re maximizing something other than health, because they incorrectly believe that theyâ€™re
better at offering the treatment, or because they inaccurately assess patients as more appropriate for
treatment than they actually are (perceiving a rightward shift in the distribution of patientâ€™s Xs).
         More insights from our model are illustrated in Figure III. In this figure, we plot the treatment
effect on the treated, ğ¸ğ¸ï¿½ğ‘Œğ‘Œğ‘–ğ‘–â„Î” |ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘–ğ‘–â„ = 1ï¿½ = ğ¸ğ¸ï¿½ğ‘Œğ‘Œğ‘–ğ‘–â„Î” |ğ¸ğ¸ï¿½ğ‘Œğ‘Œğ‘–ğ‘–â„Î” ï¿½ > ğœğœâ„ ï¿½, on the vertical axis, while the
propensity of being treated (which is a function of ğ¼ğ¼ğ‘–ğ‘–â„ ) is given on the horizontal axis. The horizontal
line at zero indicates the efficient threshold, below which the expected benefit of treatment is negative
(harm). The top curve in Figure III represents the treatment-on-the-treated effect for a patient with a
given propensity that is treated in a hospital with a high minimum threshold for treatment, i.e. it
represents ğ¸ğ¸ï¿½ğ‘Œğ‘Œğ‘–ğ‘–â„Î” |ğ¸ğ¸ï¿½ğ‘Œğ‘Œğ‘–ğ‘–â„Î” ï¿½ > ğœğœâ„ ï¿½ = ğœğœâ„ + ğ‘”ğ‘”(ğ¼ğ¼ğ‘–ğ‘–â„ ). The lower curve represents the same thing for a hospital
with a low minimum threshold. Treatment-on-the-treated approaches the minimum threshold (Ï„high or
Ï„low) for a patient with a low propensity of being treated (small value of ğ¼ğ¼ğ‘–ğ‘–â„ ), since no patient is ever
treated with a benefit below this threshold. For a patient with a high propensity of being treated (large
value of ğ¼ğ¼ğ‘–ğ‘–â„ ), truncation becomes irrelevant and the treatment-on-the-treated effect asymptotes to the
unconditional benefit of treatment. However, conditional on a patientâ€™s propensity, the treatment effect
is always higher by exactly ğœğœâ„ğ‘–ğ‘–ğ‘–ğ‘–â„ âˆ’ ğœğœğ‘™ğ‘™ğ‘™ğ‘™ğ‘™ğ‘™ in the hospital with the higher threshold.
         The graph illustrates two implications of the theoretical model. First, we can identify overuse
and underuse by focusing on patients with the lowest probability of receiving treatment. In these
patients, there is overuse when the treatment effect for the lowest propensity patients is negative, and
underuse when the treatment effect for the lowest propensity patients remains positive. In particular, a
hospital is over treating its patients (ğœğœâ„ < 0) whenever the treatment effect on the treated is negative
(indicating harm) among low propensity patients.
         Second, differences in comparative-advantage at performing reperfusion show up as a
movement along the curves â€“ higher comparative advantage at reperfusion (ğ›¼ğ›¼â„Î” ) increases the propensity
of patients to be treated, and therefore the treatment effect, but does not affect treatment effects
conditional on propensity. Being treated at a hospital with a higher comparative advantage (ğ›¼ğ›¼â„Î” ) is
equivalent to having patient characteristics (ğ‘‹ğ‘‹ğ‘–ğ‘– ğ›½ğ›½ Î”) that increase your benefits from treatment â€“ both
raise your expected benefit from treatment and therefore raise your propensity to be treated.
         In summary, the key difference between identifying comparative advantage from allocative
inefficiency is that differences in hospital comparative advantage have an impact on treatment effects
by shifting the propensity to be treated, while differences in the minimum threshold have an impact on
treatment effects conditional on the propensity to receive reperfusion.




                                                                                                                           16
II.D. Estimation
        In a potential outcomes framework, the equation relating the level of survival to treatment is:
(5)     ğ‘Œğ‘Œğ‘–ğ‘–â„ = ğ‘Œğ‘Œğ‘–ğ‘–â„0 + ğ‘Œğ‘Œğ‘–ğ‘–â„âˆ† ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘–ğ‘–â„
                                                                     0
             = ğ›¼ğ›¼â„0 + ğ‘‹ğ‘‹ğ‘–ğ‘–â„ ğ›½ğ›½0 + ğ‘Œğ‘Œğ‘–ğ‘–â„âˆ† ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘–ğ‘–â„ + ï¿½ğ‘£ğ‘£ğ‘–ğ‘–â„      0
                                                                        + ğœ€ğœ€ğ‘–ğ‘–â„ ï¿½
Here, latent survival for patient i at hospital h depends on a hospital effect that captures the hospitalâ€™s
general level of expertise (or TFP) providing usual care ğ›¼ğ›¼â„0, patient risk adjusters Xih and a patient-
specific treatment effect ğ‘Œğ‘Œğ‘–ğ‘–â„Î” . Regression estimates of this equation identify the treatment-on-the-treated
effect, ğ¸ğ¸ï¿½ğ‘Œğ‘Œğ‘–ğ‘–â„Î” ï¿½ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ = 1ï¿½, if the receipt of treatment is uncorrelated with the unobservable
                                                        0            0
characteristics of patients who were not reperfused (ğ‘£ğ‘£ğ‘–ğ‘–â„ ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ ğœ€ğœ€ğ‘–ğ‘–â„ ). This treatment-on-the-treated effect
is the same as Equation 4â€”and will be used to identify overuse (if negative) and underuse (if positive).
        It is important to see that we are not relying on the conventional `selection on observablesâ€™
                        0        1
assumption that both ğ‘£ğ‘£ğ‘–ğ‘–â„ and ğ‘£ğ‘£ğ‘–ğ‘–â„ are conditionally uncorrelated with treatment, which would imply that
receipt of treatment is uncorrelated with the gain from treatment. Indeed, we explicitly allow for
                                                                                             Î”      1
â€˜selection on gainsâ€™ where providers use information on the patientâ€™s idiosyncratic gain, ğ‘£ğ‘£ğ‘–ğ‘–â„ = ğ‘£ğ‘£ğ‘–ğ‘–â„ âˆ’
   0
ğ‘£ğ‘£ğ‘–ğ‘–â„ , to determine treatment [Wooldridge (2002, p.606)]. In our model, conditional on our control
variables, we assume that treatment is uncorrelated with omitted factors in a patientâ€™s baseline survival
    0
(ğ‘£ğ‘£ğ‘–ğ‘–â„ ), but allow for selection on gains where treatment is correlated with omitted factors in the patientâ€™s
                    Î”      1        0                                                                      Î”
unobserved gain (ğ‘£ğ‘£ğ‘–ğ‘–â„ = ğ‘£ğ‘£ğ‘–ğ‘–â„ âˆ’ ğ‘£ğ‘£ğ‘–ğ‘–â„ ). Thus, instead of assuming that treatment is uncorrelated with ğ‘£ğ‘£ğ‘–ğ‘–â„
                       0         Î”
we must assume that ğ‘£ğ‘£ğ‘–ğ‘–â„ and ğ‘£ğ‘£ğ‘–ğ‘–â„ are conditionally uncorrelated. We think these assumptions are plausible
given our rich data and the nature of the reperfusion treatment decision.
                                                              0
        The assumption that treatment is uncorrelated with ğ‘£ğ‘£ğ‘–ğ‘–â„ is plausible given the rich covariates that
we have. The chart data collected in the CCP was focused on patient factors that predict outcomes, so
there is some reason to think that the CCP included all data from the patientâ€™s chart that physicians
                                                                           0         Î”
would use to predict baseline mortality (v0). While the assumption that ğ‘£ğ‘£ğ‘–ğ‘–â„ and ğ‘£ğ‘£ğ‘–ğ‘–â„ are uncorrelated is a
strong one, we think there are a number of reasons that it is more likely in our setting than assuming
                                  Î”
treatment is uncorrelated with ğ‘£ğ‘£ğ‘–ğ‘–â„ . First, because reperfusion is a treatment that must be done quickly
after admission, the physician is not able to wait and observe the patientâ€™s outcome without treatment
(ğ‘Œğ‘Œğ‘–ğ‘–â„0 ). Thus, the physicianâ€™s belief about the benefit from reperfusion (ğ‘£ğ‘£ğ‘–ğ‘–â„
                                                                               Î”
                                                                                  ) is unlikely to be driven by
knowledge of a patientâ€™s baseline outcome (ğ‘Œğ‘Œğ‘–ğ‘–â„0 ). This would not be the case in many settings in which
people get to see their actual outcome in the untreated state (e.g. workers may enroll in training because
their current job is going poorly, and heart attack patients may not receive bypass because they died
before being stabilized).



                                                                                                            17
        Second, unlike many surgical treatments, the benefits of reperfusion are not closely related to
baseline mortality risk. The key question is whether gains from treatment (and selection into treatment)
are driven by baseline mortality risk. For some treatments the answer is yes â€“ e.g. invasive surgical
treatments, or treatments that occur weeks after index admission, are much less successful if the patient
is at high risk of death (patient is too frail to absorb the physical trauma of the procedure, or does not
survive/stabilize to get eventual treatment). For reperfusion, this is less likely to be true because it
happens immediately, and it is less invasive, so that success depends less on how frail the patient is and
more on specific patient conditions that put them at risk for complications such as bleeding. Thus, the
benefits of the treatment are specific to reperfusion, rather than a direct function of baseline mortality
risk.
        Third, many idiosyncratic factors occurring in the hospital that are unrelated to a patientâ€™s
baseline mortality may affect the benefits of reperfusion. For example, whether a patient gets treated
with reperfusion depends on factors such as the experience of the particular doctor and team as well as
the capacity of the hospital at the moment of the patientâ€™s arrival. Providers observe these factors (which
      1
are ğ‘£ğ‘£ğ‘–ğ‘–â„ ) , that are idiosyncratic to every patient situation, and act on them.
        While we think the selection on gains assumption is defensible on a priori grounds, it is still a
strong assumption. In the results section, we provide evidence supporting the case that we can estimate
the treatment on treated effect, including comparing our estimates to evidence from randomized trials.
        Our test for allocative efficiency requires comparing the treatment on the treated parameter
across hospitals, while holding the propensity to receive treatment constant. The index for the propensity
to receive treatment, ğ¼ğ¼ğ‘–ğ‘–â„ , was obtained from a random-effects logit model of treatment receipt on the
patient risk adjusters (ğ‘‹ğ‘‹ğ‘–ğ‘–â„ ) and hospital-level random intercepts (ğœƒğœƒâ„ ) estimated using xtmelogit in Stata.
Bayesian posterior estimates of the hospital random effects (ğœƒğœƒï¿½â„ ), commonly referred to in the literature
as shrinkage estimates, were used as estimates of ğœƒğœƒâ„ . For more details see Appendix II.
        Using the fact that OLS estimates of Equation (5) estimate treatment on the treated, we can plug
in our modelâ€™s implication for treatment on treated from Equation (4) into Equation (5) to yield:
                                                                                  0       0
(6)      ğ‘Œğ‘Œğ‘–ğ‘–â„ = ğ›¼ğ›¼â„0 + ğ‘‹ğ‘‹ğ‘–ğ‘–â„ ğ›½ğ›½ 0 + ï¿½ğœğœâ„ + ğ‘”ğ‘”(ğ¼ğ¼ğ‘–ğ‘–â„ )ï¿½ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘–ğ‘–â„ + ğ‘£ğ‘£ğ‘–ğ‘–â„ + ğœ€ğœ€ğ‘–ğ‘–â„
To estimate Equation (6), we consider two approximations to the function ğ‘”ğ‘”(ğ¼ğ¼): a linear approximation
(ğ‘”ğ‘”(ğ¼ğ¼) = ğœ†ğœ†ğ‘œğ‘œ + ğœ†ğœ†1 ğ¼ğ¼), and a more flexible approximation using indicator variables for the 100 percentiles
of that allows ğ‘”ğ‘”(ğ¼ğ¼) to have any shape (ğ‘”ğ‘”(ğ¼ğ¼) = âˆ‘100
                                                   ğ‘ğ‘=1 ğ›¿ğ›¿ğ‘ğ‘ 1ï¿½ğ‘”ğ‘”ğ‘ğ‘âˆ’1 < ğ¼ğ¼ < ğ‘”ğ‘”ğ‘ğ‘ ï¿½). While the theory only

predicts a monotonic relationship, we find that estimates from a simple linear specification are very
similar to those that allow g(I) to have a completely flexible form. We will exploit the linear specification
later in the paper, where we impose additional parametric structure to recover hospital measures of ğ›¼ğ›¼â„Î” .



                                                                                                            18
           Adding these approximations for g(I) into Equation (6) yields estimating equations:
                                                                                                                              0       0
(6a) ğ‘Œğ‘Œğ‘–ğ‘–â„ = ğ›¼ğ›¼â„0 + ğ‘‹ğ‘‹ğ‘–ğ‘–â„ ğ›½ğ›½ 0 + ğœğœâ„ ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘–ğ‘–â„ + ğœ†ğœ†0 ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘–ğ‘–â„ + ğœ†ğœ†1 ğ¼ğ¼ğ‘–ğ‘–â„ ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘–ğ‘–â„ + ğ‘£ğ‘£ğ‘–ğ‘–â„ + ğœ€ğœ€ğ‘–ğ‘–â„
                                                                                                                              0       0
(6b) ğ‘Œğ‘Œğ‘–ğ‘–â„ = ğ›¼ğ›¼â„0 + ğ‘‹ğ‘‹ğ‘–ğ‘–â„ ğ›½ğ›½0 + ğœğœâ„ ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘–ğ‘–â„ + âˆ‘100
                                                             ğ‘ğ‘=1 ğ›¿ğ›¿ğ‘ğ‘ 1ï¿½ğ‘”ğ‘”ğ‘ğ‘âˆ’1 < ğ¼ğ¼ğ‘–ğ‘–â„ < ğ‘”ğ‘”ğ‘ğ‘ ï¿½ âˆ— ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘–ğ‘–â„ + ğ‘£ğ‘£ğ‘–ğ‘–â„ + ğœ€ğœ€ğ‘–ğ‘–â„

Here, the hospital-specific coefficient on treatment identifies differences across hospitals in ğœğœâ„ . Note
that separating the average level (as opposed to differences across hospitals) of ğœğœâ„ from the intercept of
ğ‘”ğ‘”(ğ¼ğ¼) would require stronger parametric assumptions, so we focus on identifying differences between
hospitals (which are indications of allocative inefficiency). In the linear specification, we demean ğ¼ğ¼ğ‘–ğ‘–â„ to
have a value of 0 for the average treated patient so that the coefficient ğœ†ğœ†0 captures the average effect of
reperfusion among the treated. The hospital-specific intercept in this regression identifies hospital TFP
(ğ›¼ğ›¼â„0 ). The coefficient (ğœ†ğœ†1 ) on the interaction ğ¼ğ¼ğ‘–ğ‘–â„ ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘–ğ‘–â„ or on the indicator variables for the
percentiles of g(I) provide a test for whether the benefit of reperfusion therapy is increasing with the
propensity to receive such treatmentâ€”as would be the case if a Roy Model of treatment allocation was
at work, as opposed to model where providers select patients randomly or without regard to benefits.
           Estimating Equations (6a) and (6b) involves estimating hospital-specific coefficients on
treatment rates for thousands of hospitals. Rather than including hospital dummies interacted with
treatment, which would yield imprecise estimates and suffer from small sample problems, we estimate
hierarchical logit models for survival with hospital-level correlated random coefficients for the hospital-
specific intercept and slope (ğ›¼ğ›¼â„0 and ğœğœâ„ ). We document that key results are similar using fixed effect
models.
           We also consider an alternative specification that allows for a relatively straightforward test for
allocative inefficiency while avoiding the necessity of estimating hospital-specific coefficients. Recall
that the risk-adjusted hospital reperfusion rate (the hospital intercept from Equation 2) is ğœƒğœƒâ„ = ğ›¼ğ›¼â„Î” âˆ’ ğœğœâ„ ,
and we obtain estimates ğœƒğœƒï¿½â„ of this intercept (up to scale) from estimating the propensity equation. Under
two extreme cases, we can say how treatment on the treated (ğœğœâ„ + ğ‘”ğ‘”(ğ¼ğ¼ğ‘–ğ‘–â„ )) is related to ğœƒğœƒâ„ . In the first
case, if there is no allocative inefficiency (ğœğœâ„ = 0) then ğœƒğœƒâ„ = ğ›¼ğ›¼â„Î” and variation in reperfusion across
hospitals is driven purely by comparative advantage. In this case, ğœƒğœƒâ„ is unrelated to the treatment effect
on the treated after conditioning on the propensity (since in this case ğœğœâ„ + ğ‘”ğ‘”(ğ¼ğ¼ğ‘–ğ‘–â„ ) = ğ‘”ğ‘”(ğ¼ğ¼ğ‘–ğ‘–â„ )). At the other
extreme, if there is no variation in comparative advantage (ğ›¼ğ›¼â„Î” = 0) then ğœƒğœƒâ„ = âˆ’ğœğœâ„ and variation in
reperfusion across hospitals is driven purely by treatment thresholds. In this case, ğœƒğœƒâ„ will be negatively
related to the treatment effect on the treated after conditioning on the propensity (since in this case ğœğœâ„ +
ğ‘”ğ‘”(ğ¼ğ¼ğ‘–ğ‘–â„ ) = âˆ’ğœƒğœƒâ„ + ğ‘”ğ‘”(ğ¼ğ¼ğ‘–ğ‘–â„ )).




                                                                                                                                           19
           These two extreme cases suggest including an interaction between ğœƒğœƒï¿½â„ and treatment in Equations
(6), rather than estimating hospital-specific coefficients on treatment, as a simple test for allocative
inefficiency. Therefore, we estimate specifications of the form:
(7a) ğ‘Œğ‘Œğ‘–ğ‘–â„ = ğ›¼ğ›¼â„0 + ğ‘‹ğ‘‹ğ‘–ğ‘– ğ›½ğ›½ 0 + ğœ†ğœ†2 ğœƒğœƒï¿½â„ ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘–ğ‘–â„ + ğœ†ğœ†0 ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘–ğ‘–â„ + ğœ†ğœ†1 ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘–ğ‘–â„ âˆ— ğ¼ğ¼ğ‘–ğ‘–â„ + ğ‘£ğ‘£ğ‘–ğ‘–â„
                                                                                                                                    0       0
                                                                                                                                       + ğœ€ğœ€ğ‘–ğ‘–â„
(7b) ğ‘Œğ‘Œğ‘–ğ‘–â„ = ğ›¼ğ›¼â„0 + ğ‘‹ğ‘‹ğ‘–ğ‘–â„ ğ›½ğ›½0 + ğœ†ğœ†2 ğœƒğœƒï¿½â„ ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘–ğ‘–â„ + âˆ‘100                                                              0
                                                                  ğ‘ğ‘=1 ğ›¿ğ›¿ğ‘ğ‘ 1ï¿½ğ‘”ğ‘”ğ‘ğ‘âˆ’1 < ğ¼ğ¼ğ‘–ğ‘–â„ < ğ‘”ğ‘”ğ‘ğ‘ ï¿½ âˆ— ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘–ğ‘–â„ + ğ‘£ğ‘£ğ‘–ğ‘–â„ +
   0
ğœ€ğœ€ğ‘–ğ‘–â„
If the coefficient on the interaction (ğœ†ğœ†2 ) is zero, this suggests that variation in hospital-level reperfusion
rates was entirely driven by comparative advantage in treatment (case 1 above). Alternatively, if the
coefficient on the interaction is negative, this suggests that variation in hospital-level reperfusion is
associated with allocative inefficiency. This simple specification provides an intuitive test of the key
insights from our model: conditional on propensity, higher treatment rates due to comparative advantage
will be unrelated to treatment effects, while higher treatment rates due to lower treatment thresholds will
be negatively related to treatment effects.


                                                               III. RESULTS
III.A. Identifying Allocative Inefficiency
           Our model implies that if treatment is being allocated efficiently, then patients with a higher
propensity to be treated for any reason should have higher expected benefit from the treatment, and two
patients with the same propensity should have the same expected benefit from treatment. Allocative
inefficiency can be identified when the benefit of treatment differs across hospitals for patients with the
same propensity to be treated. In Figure IV, we evaluate these implications graphically by plotting the
estimated survival benefit from reperfusion and 95% CI against a patientâ€™s treatment propensity index
(Iih) for patients treated in different hospitals. The graphs do not impose structure on the data and are
designed to graphically illustrate the main findings of our paper using simple and transparent plots that
can be easily replicated by others. These graphs are similar to Figure I, only now we include the hospital

effect Î¸Ë†h in the propensity, as suggested by our model.

           The treatment benefit at each point in the distribution of the propensity to receive care was
estimated flexibly using a local-linear version of equation 6a with a triangular kernel that included 30%
of the sample on either side. The patientâ€™s treatment propensity was obtained from hierarchical logit
estimation of equation (2), and is demeaned so that 0 is the propensity for an average patient receiving
reperfusion. We estimate separate panels for hospitals in the lowest tercile and highest tercile of the

estimated hospital effect ( Î¸Ë†h ), also estimated from the propensity equation (2), as described in Appendix




                                                                                                                                                 20
II. These hospital effects are estimates of the risk-adjusted reperfusion rate at each hospital, so hospitals
in the top tercile are those that treat patients more aggressively; the distribution of hospital-effects is
also graphed in the appendix.       As noted there, we estimate hospital random-effects which allow for
empirical Bayes shrinkage. Empirical Bayes reduces prediction error in the estimates of the hospital
effects by shrinking standard hospital fixed-effect estimates back toward zero, particularly for small
hospitals with noisy estimates. In the appendix, we show that OLS and logit models with random and
fixed-effects generate very similar (correlation>.97) estimates of the impact of patient characteristics
(ğ‘‹ğ‘‹ğ‘–ğ‘– ğ›½ğ›½Ì‚ ) and unshrunk estimates of hospital effects (ğœƒğœƒï¿½â„ ). However, the use of shrinkage does matter for the
estimates of hospital effects because of the substantial number of small hospitals in our sample: The
correlation between the shrunk and unshrunk random effect from the logit model is only 0.88.
         Both plots show a strong upward slope, with higher benefit from treatment for patients with a
higher propensity to receive reperfusionâ€”and exactly mirror the theoretical illustration in Figure 3. But
at every propensity, the benefits of reperfusion are lower in the top-tercile hospitals, as would be
expected if higher treatment rates were due to lower treatment thresholds. At the lowest propensity
levels, the survival benefits from reperfusion are significantly negative for the top-tercile hospitals,
suggesting that there is overuse among these hospitals. In the bottom-tercile hospitals, the estimated
survival benefits from reperfusion for the lowest propensity patients are less negative and not
significantly different from zero, which is consistent with appropriate use of reperfusion in these
hospitals. Finally, we note that plots are also linear in log-odds despite the non-parametric nature of the
estimationâ€” this will allow us to use logit models that control for the propensity linearly as in Equations
6a and 7a. 9 The linearity in log-odds result was not implied by our model, but it will greatly simplify
our empirical work.
         Figure V is similar to Figure IV, but plots the estimated survival benefit from reperfusion and

95% CI against the hospital effect from the propensity equation ( Î¸Ë†h ), controlling non-parametrically

for the propensity index (a local linear estimate of Equation 7b). The hospital-effects are mean zero. The
left-hand panel included all patients, while the right-hand panel was estimated only for low-propensity
patients whose propensity index implied that they had below a 20% probability of receiving reperfusion.
Both plots show a clear downward slope, with lower benefit from treatment for patients treated by

hospitals with higher risk-adjusted reperfusion rates ( Î¸Ë†h ). Again, this would be expected if higher

treatment rates were due to lower treatment thresholds, and is evidence of allocative inefficiency.

9
 Changes in log-odds (i.e. logit coefficients) can be approximately converted into absolute changes in
probability by multiplying them by p x (1-p), where p is the probability of success. Table 1 reports 30-day
survival as 80%, so a change of .3 in log-odds means a .3x.8.x2=4.8 percentage points increase in survival.



                                                                                                              21
Among all patients (the left-hand plot), the estimated survival benefit from reperfusion is positive for
all hospitals, although it is small and not significant in hospitals with the highest treatment rates (those

2 standard deviations above average, with Î¸Ë†h =0.6). In contrast, among the lowest propensity patients

(the right-hand plot), only hospitals with the lowest treatment rates are estimated to have survival
benefits from reperfusion that are near to zero. The estimated survival benefit from reperfusion is
negative and significant in hospitals with average or higher treatment rates, suggesting that there is
overuse in most hospitals, i.e., we were able to identify substantial subsets of low-propensity patients
who were harmed by reperfusion treatment in most hospitals.
        Table II reports regression estimates of equation 7a and 7b that are analogous to the results
reported in the figures. The table reports estimates of the effect of reperfusion on 30-day survival
allowing for interactions of reperfusion with the propensity index (Iih) and the hospital effect from the

propensity equation ( Î¸Ë†h ). The regressions control for patient characteristics and include hospital fixed-

effects, as the theory tells us to condition on them. To help with interpretation, we have normed the
propensity-index so that a value of 0 refers to the average patient receiving reperfusion. Thus, the
coefficient on reperfusion is an estimate of the effect of reperfusion on an average patient receiving
reperfusion. The first four columns report OLS estimates and the last three report logit estimates where
the coefficients are odds ratios.

        Column (1) does not include the interactions of reperfusion with Î¸Ë†h , but it is included to

demonstrate that the benefit of reperfusion is clearly increasing in the propensity to receive reperfusion,
and consequently, that a Roy-model of triage describes provider decision making. The coefficient on
the interaction of reperfusion with the propensity index is positive and highly significant, implying that
the treatment effect of reperfusion on survival is increasing in the patientâ€™s propensity index as predicted
by our model. The coefficient on this interaction implies that an increase in the propensity index of one
(about one standard deviation of the propensity index in the treated population) is associated with
roughly a doubling of the treatment effect. Thus, it appears that hospitals are choosing patients for
treatment based on the benefit of the treatment, and the heterogeneity in the treatment effect is large
relative to the average treatment effect.
        In column 2, we add an interaction of reperfusion with the hospital effect from the propensity

equation ( Î¸Ë†h ). The coefficient on this interaction is negative and significant, meaning that conditional

on a patientâ€™s propensity, more aggressive hospitals (those with a higher propensity to treat patients, Î¸Ë†h

) have lower returns to reperfusion. As noted earlier, and consistent with the simpler graphical evidence




                                                                                                         22
presented before, this is evidence of allocative inefficiency â€“ if a hospitalâ€™s high use of reperfusion was
entirely due to comparative advantage, we would get a coefficient of 0 on this variable. The negative
coefficient is consistent with what would be expected if the variation was due to differences in thresholds
(Ï„), where more aggressive hospitals have lower minimum thresholds for treatment, treat more patients,
and have lower benefits to treatment. In column 3 we control for the propensity-index through a mills
ratio and note that this type of control is quite similar to controlling for the index linearly. 10 The
coefficient is similar in column 4, where we non-parametrically control for the interaction of reperfusion
with a set of 100 dummies for each propensity percentile, suggesting that controlling for the linear
interaction of propensity with reperfusion is a sufficient approximation to g(I). The last three columns
of Table II are logit analogs to the earlier OLS regressions, and yield similar results in logodds terms.
The estimated coefficients suggest that a one standard deviation increase in the hospital effect from the
propensity equation (about 0.3) lowers the survival benefit of reperfusion by about 1 percentage point
or lowers the odds of survival by about 7%.
         In Table III we estimate the logit models for 7-day and 360-day survival to investigate the
sensitivity of our results to alternative survival windows. The purpose of using 7-day survival was to
examine whether the patterns noted above are evident soon after admission and reflect decisions about
how the heart-attack was initially treated. If they do not appear at 7-day survival, the concern would be
that we are picking up the effect of later treatmentsâ€”for example, the quality of post-discharge care. At
7 days relative to 30 days, we expect the effect of the treatment to be even more tightly linked to a
patientâ€™s propensity to receive it and that is exactly what we find in Panel A. This relationship is half as
strong for 360-day survival (Panel B) relative to 7-day survival, and represents the importance of post-
discharge factors in affecting 360-day survival. In both panels, the benefits of reperfusion fall in
hospitals that do more of it which is consistent with allocative inefficiency, as more aggressive hospitals
work into less appropriate patients.
        The regressions in Tables II and III identify allocative inefficiency indirectly, by estimating

whether a particular hospital-level characteristic ( Î¸Ë†h ) is associated with the survival benefit of

reperfusion, after controlling for patient propensity. A more direct approach is to estimate how much
the survival benefit of reperfusion varies across hospitals, after conditioning on patient propensity. In
Table IV, we do this by estimating Equation 6a using hierarchical (mixed effects) logit models that treat



10
   In the columns with a mills-ratio control for the propensity index, we took the propensity Pr(Reperfusion=1|X)
from the treatment logit, put it through an inverse normal to get the equivalent probit index, then created the
mills-ratio using that probit index. We did this for ease of comparability across columns and avoiding a
comparison of probit coefficients to logit and OLS coefficients.



                                                                                                              23
the hospital-specific intercept and reperfusion coefficient as correlated random effects (these models
side-step the challenges of fixed-effects estimation for small hospitals). The first column of Table IV
reports results from estimating a logit model that only includes a hospital-level random intercept to
account for the hospitalâ€™s general level of expertise (or TFP) at providing usual care (ğ›¼ğ›¼â„0 ). The random
effects assumption may appear to be restrictive relative to the fixed effect models in Table II, but the
restrictions   do   not   meaningfully    change    the   estimated    coefficients   on    reperfusion   or
reperfusion*propensity.
        The second column of Table IV estimates the logit with both a hospital-level random intercept
and a hospital-level random coefficient on reperfusion, allowing us to estimate the variance and
correlation in both the hospital-level TFP (ğ›¼ğ›¼â„0 ) and the hospital-level thresholds (ğœğœâ„ ). We find that the
standard deviation of hospital thresholds is large (.313 in logodds) â€”and of the same magnitude as the
effect of reperfusion for the average treated patient (.314). There is also considerable variation across
hospitals in TFP, as seen by the standard deviation of ğ›¼ğ›¼â„0 estimated to be .198. This estimate implies that
the standard deviation across hospitals in the risk-adjusted odds of survival for patients not receiving
reperfusion is nearly 20 percent (or nearly 4 percentage points off a base survival rate of 81 percent).
Finally, we estimate that the hospital-level coefficient on reperfusion is negatively correlated with the
hospital-level intercept, meaning that hospitals with higher thresholds (conservative hospitals that do
less) have worse outcomes for patients not receiving reperfusion. Later in the paper we find evidence
that this stems from hospitals that are worse at caring for patients without reperfusion being unaware,
especially if theyâ€™re small, that the benefits from doing more reperfusion are actually high for them.


III.B. Evidence Supporting Key Assumptions
        Our analysis relies on three key assumptions: (1) that hospitals triage patients according to a
Roy-model; (2) the â€˜single-indexâ€™ assumption, that the distribution of unobservables does not have a
hospital specific component; and (3) that we are able to estimate a â€˜treatment on the treatedâ€™ parameter.
We examine each of these in turn. Finally, we discuss other relevant issues including our decision to
ignore costs and the possibility that comparative advantage and allocating inefficiency are not just
hospital-level objects, but vary with patient characteristics.


Roy Selection: We have presented evidence supporting the first assumption in Figure IV and Table II,
which document that the benefit of reperfusion is clearly increasing in the propensity to receive
reperfusion. Thus, it appears that hospitals are choosing patients for treatment based on the benefit of
the treatment. This evidence is not consistent with other possible selection rules that would imply no



                                                                                                          24
relationship or even a negative relationship between the propensity and benefit. For example, we would
expect no relationship if selection were based on non-medical factors such as ability to pay or availability
of needed personnel at the time of admission. Alternatively, we would expect a negative relationship
between propensity and benefit if hospitals were more likely to treat patients who were about to die in
a futile, last-ditch effort.


Single Index: If some hospitals have a wider distribution of unobservable gains from treatment (ğ‘£ğ‘£ âˆ† ),
because of patient selection or superior diagnostics, it will increase the return to treatment at these
hospitals, but the mechanism would be patientsâ€™ unobserved characteristics, not allocative inefficiency
in the form of higher hurdles. This can be tested by examining whether the relationship between
treatment effect and propensity-index varies by selected hospital characteristics: hospitals with more
variation in ğ‘£ğ‘£ âˆ† (gains in treatment unobserved to us but observable to the hospital, say through better
diagnostics) will have a flatter relationship between propensity and the return to treatment relative to
other hospitals. There are two reasons for this: (i) the propensity estimates Î²/Ïƒv so as Ïƒv increases, the
index captures less about benefit relative to the increased variance of ğ‘£ğ‘£ âˆ† and (ii) an increase in Ïƒv would
push relatively more low-propensity patients over the hurdle and this would flatten the relationship
between returns and the propensity.
         This test is implemented by adding a triple interaction (Reperfusion*Index*Hospital
Characteristics) between hospital characteristics like (risk-adjusted) hospital treatment rates, volume,
and major-teaching hospital and seeing whether the effect of Reperfusion*Index on survival varies by
these characteristics. If these triple interactions are significant then it is evidence against our hypothesis
that conditional on the Xâ€™s, the distribution of ğ‘£ğ‘£ âˆ† is identical across hospitals. This would be different
than a parallel shift in the returns to treatment that would be generated by a model of allocative
differences (as in Figure II).
         We test this hypothesis in Table V. If we thought that hospitals with high treatment rates had
access to superior diagnostic technology or somehow received patients with better unobservable
characteristics, then theyâ€™d have a higher variance of ğ‘£ğ‘£ âˆ† , not higher tau, and the triple-interaction would
be negative to reflect the flatter relationship. We do not see this; the coefficient on the triple interaction
in the first column is essentially zero. But if hospitals with higher risk-adjusted treatment rates have
lower hurdles (negative tau), then the coefficient on Reperfusion *Hospital-Effect should be negative
because this is a story about hurdles (Ï„) and implies a parallel shift down conditional on propensityâ€”
this is exactly what we find. In the remaining columns we estimated triple interactions with other
hospital characteristics like volume and major-teaching. Here too, we found that the triple interactions



                                                                                                           25
were insignificant, and interpreted that as being reassuring for the credibility of our empirical work (OLS
models gave very similar results).


        Estimating Treatment-on-the-Treated: To evaluate the plausibility of this assumption we
estimated a simple logit model for the impact of reperfusion on 30-day mortality, controlling for the rich
patient risk-adjusters in the CCP data, and compared our estimates to those obtained from clinical trials.
Clinical trials in medicine have highly specific and strict exclusion criteria based on contraindications
and prior histories and therefore estimate the effect of the treatment on patients who will likely receive
the treatment. For this reason, we think that the CCP data and the RCTs should recover similar treatment-
on-treated effects. A summary of nine trials was published in the journal Lancet by the Fibrinolytic
Therapy Trialistsâ€™ Collaborative Group (1994). This was the same time-period as the CCP data and each
trial evaluated reperfusion therapy in heart-attack patients. Across these nine trials, reperfusion within
12 hours reduced 35-day mortality from 11.5% to 9.6%, which implies that the treatment on the treated
effect of reperfusion on the log-odds of survival is 0.20. In our CCP data, a logit model controlling for
the CCP risk-adjusters estimates an identical effect, with reperfusion increasing the log-odds of survival
by 0.207 (S.E. = 0.025). We take this evidence as supporting the case that we can estimate unbiased
estimates of the treatment on treated effect.
        Because of the centrality of the treatment-on-treated parameter to our model, we further
explored the plausibility of the modelâ€™s identifying assumptions. In our model, conditional on our
control variables, we assume that treatment is uncorrelated with omitted factors in a patientâ€™s baseline
             0
survival (ğ‘£ğ‘£ğ‘–ğ‘–â„ ), but allow for selection on gains where treatment is correlated with omitted factors in the
                              Î”      1        0                                  0         Î”
patientâ€™s unobserved gain (ğ‘£ğ‘£ğ‘–ğ‘–â„ = ğ‘£ğ‘£ğ‘–ğ‘–â„ âˆ’ ğ‘£ğ‘£ğ‘–ğ‘–â„ ). Thus, we must assume that ğ‘£ğ‘£ğ‘–ğ‘–â„ and ğ‘£ğ‘£ğ‘–ğ‘–â„ are conditionally
uncorrelated. While we cannot test this assumption directly, we can test for a similar pattern in
observables: as we add more detailed information about the patient to our controls, the additional
                                                   Î”                                              0
controls may predict treatment (correlated with ğ‘£ğ‘£ğ‘–ğ‘–â„ ) and predict mortality (correlated with ğ‘£ğ‘£ğ‘–ğ‘–â„ ) but
                                                                            Î”                       0
should not change the estimated effect of treatment on survival (because ğ‘£ğ‘£ğ‘–ğ‘–â„ uncorrelated with ğ‘£ğ‘£ğ‘–ğ‘–â„ ).
        Table VI reports results from logit models of survival on reperfusion with increasingly detailed
controls. The first column includes no controls, and estimates an impact of reperfusion on the logodds
of survival of 0.424, well above the trial estimates and implying that some level of controls are needed
for our assumptions to hold. The second column adds age-sex-race controls, and estimates a treatment
effect of 0.192, in line with trial estimates. The third column adds all of the CCP risk adjusters, and
yields a similar estimate of the treatment effect of 0.207. Thus, while the additional CCP risk-adjusters




                                                                                                            26
are very strong predictors of both treatment (p<.001) and survival (p<.001), controlling for them has
very little impact on the estimated treatment effect, which is consistent with our identifying assumptions.
          In the final column we add two types of additional controls that were not on the patientâ€™s chart
(so were not included in our baseline specification) but were added to the data later and are highly
predictive (p<.001) of both survival and treatment: patient zip-code characteristics (average income and
fraction with a high school and college degree); and American Hospital Association and American
College of Cardiology (AHA/ACC) criteria for reperfusion and cardiac catheterization that were created
for each patient by expert reviewers using the chart data (where ideal patients for a treatment are those
for whom the treatment would almost always be indicated, and less-than-ideal candidates are patients
for whom the therapy would be controversial). Controlling for these additional variables yields an
estimate of the treatment effect (0.199) that is similar to models with fewer controls and similar to the
trial estimates. This provides further support for our conditional independence assumption â€“ omitted
                                        Î”
factors driving treatment decisions (ğ‘£ğ‘£ğ‘–ğ‘–â„ ) appear to be uncorrelated with omitted factors determining
             0
survival (ğ‘£ğ‘£ğ‘–ğ‘–â„ ).
          The fact that we can replicate trial estimates with simple age-sex-race controls is context specific
â€“ reperfusion with thrombolytics is a non-invasive treatment whose benefits are not strongly related to
mortality risk, unlike surgical interventions which are less likely to be successful in frail populations.
Thus, after conditioning on age-sex-race, the factors that drive treatment in our setting are not strongly
related to the factors that determine survival. In our application, the main advantage of the rich control
variables available in the CCP is to allow more accurate estimation of variation in treatment propensity
across patients and hospitals. 11 So the key takeaway is that the CCP controls clearly matter, but the basic
patterns noted in the paper are robust to relying only on age-race-gender as control variables (additional
robustness tests using age-sex-race as the only controls are provided in Appendix III).


          Comparative Advantage and Allocative Inefficiency Vary by Patient Characteristics: while not
an identifying assumption, one might think that comparative-advantage and allocative efficiency vary
by patient characteristicsâ€”that they are larger or smaller for certain types of patients. This can be tested
by letting the coefficients on the patient characteristics vary by the risk-adjusted hospital treatment rate
(Î˜). To do this, we estimate separate propensity models by three terciles of theta and correlate their


11
   For example, estimates of the propensity using only age-sex-race controls predict only 20% of the variation
that is predicted by the propensity using the full CCP controls. Thus, if we re-estimate Table 2 controlling for
age-sex-race (but using the original full-CCP propensity estimates) we get very similar results, but if we re-
estimate Table 2 using age-sex-race controls in both the propensity and the survival equation we get similar signs
and significance, but different magnitude estimates (see online Appendix III for these results)



                                                                                                               27
predictions. If hospitals with high or low treatment rates weight patient characteristics differently, we
would find weak correlations across the terciles. Empirically, the correlations across the indices is
greater than 0.99 for terciles 1 and 2 and terciles 2 and 3. It is 0.98 for the correlation between tercile 1
and 3.


         Incorporating Costs: We have assumed that hospitals maximize survival and donâ€™t think about
costs. We could assume that hospitals arenâ€™t just maximizing survival, but rather, maximizing Net
Benefit=Survival - Î»Cost, where Î» represents the value of life, measured as survival per $1000 of
spending. Î» captures the trade- off being made by the patient and physician between improved survival
and increased costs. In our data, receiving reperfusion increases 1-year spending by $2.3k. Following
the literature, we assume that every AMI patient who lives to one year, lives on average, to 5 years. A
typical value of Î» used in cost-effectiveness studies would place the societal value of a life year at around
$100,000 (Cutler, 2004), although hospitals may use Î»=0 if patients do not pay directly for the cost of
treatment (e.g., because of insurance), or if providers have strong incentives to ignore costs (and social-
welfare) and maximize survival (e.g., perhaps because of fee-for-service payments).
         Using these numbers, an extremely low value of life would be to value each life-year at $20k,
which would generate Î»=0.01. For a value of life-year of $100k, weâ€™d get Î»=0.002. At the other extreme,
one could assume that hospitals value a life-year at $300,000 (which is highly cost-ineffective); this
would generate Î»=0.00067. These values represent the increased probability of 1-year survival at which
costs become relevant. Given that the reperfusion increases 1-year survival by 4 percentage points
(0.04), and increases spending by $2.3k, costs become irrelevant, or at-best third-order important. 12


III.C. Identifying Hospital Comparative Advantage
         To summarize the evidence so far, we have shown that (i) patients with higher appropriateness
receive higher benefits from treatment, (ii) this relationship is approximately linear, which is why
simpler linear-controls for the propensity to receive care do as well as non-parametric controls for the
propensity to receive care, (iii) less appropriate patients are harmed in high-reperfusion hospitals, which
is consistent with overuse, (iv) more aggressive hospitals have lower average treatment benefits for


12
  What is relevant for our analysis is whether more aggressive hospitals are less costly on a per unit basis (this
would happen if they do more reperfusion which increases costs but this therapy has offsetting effects on 1-year
hospital and physician spending). The difference in 1-year spending from reperfusion across the most and least
intensive terciles of reperfusion is $164. There is no reasonable value of Î» at which a $150-$200 difference in
spending becomes salient to offset our emphasis on survival.




                                                                                                                28
patients at every propensity, which is consistent with these hospitals having a lower treatment threshold,
and (v) after conditioning on patient propensity there remains substantial variation in the survival benefit
of reperfusion across hospitals, which is consistent with allocative inefficiency. While these results
identify the presence of allocative inefficiency in the presence of comparative advantage, they say
nothing about the presence or absence of comparative advantage. In order to simultaneously estimate
variation in hospital thresholds and comparative advantage, we now turn to a more parametric
framework to estimate both quantities.
           In this section, we jointly estimate the treatment propensity and survival equations, yielding
estimates of the joint distribution of the hospital-level parameters (ğœƒğœƒâ„ , ğ›¼ğ›¼â„0 , ğœğœâ„ ). This approach will require
us to make assumptions about the scale parameter (Ïƒv), which is the variance of the unobservable gain
from treatment. Our earlier results on the presence of allocative-inefficiency were invariant to this
scaling, but it will turn out to be central for the recovery of comparative-advantage. These estimates are
then used to identify variation across hospitals in comparative advantage. We will rely on the linear-
approximation for g (I ) = Î»0 + Î»1I instead of the non-parametric control to simplify things (the linear

assumption was justified by Figure IV and in Table II where we showed very similar results with this
restriction compared to the fully non-parametric approach).
           To motivate our approach to recovering hospital-level comparative advantages, recall that the
treatment propensity was estimated using a random effect logit to estimate Equation 2:
(2)        Pr(ğ‘‡ğ‘‡ğ‘Ÿğ‘Ÿğ‘Ÿğ‘Ÿğ‘Ÿğ‘Ÿğ‘Ÿğ‘Ÿğ‘Ÿğ‘Ÿğ‘Ÿğ‘Ÿğ‘Ÿğ‘Ÿğ‘Ÿğ‘Ÿğ‘–ğ‘–â„ = 1) = F(ğ‘‹ğ‘‹ğ‘–ğ‘–â„ ğ›½ğ›½ + ğœƒğœƒâ„ )
Note that since ğ¼ğ¼ğ‘–ğ‘–â„ = ğ‘‹ğ‘‹ğ‘–ğ‘–â„ ğ›½ğ›½ + ğœƒğœƒâ„ , equation 6a can we rewritten as:
                                                                                                                     0       0
(7c) ğ‘Œğ‘Œğ‘–ğ‘–â„ = ğ›¼ğ›¼â„0 + ğ‘‹ğ‘‹ğ‘–ğ‘–â„ ğ›½ğ›½0 + ğœ†ğœ†0 ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘–ğ‘–â„ + (ğœ†ğœ†1 ğœƒğœƒâ„ + ğœğœâ„ )ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘–ğ‘–â„ + ğœ†ğœ†1 ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘–ğ‘–â„ âˆ— ğ‘‹ğ‘‹ğ‘–ğ‘– ğ›½ğ›½ + ğ‘£ğ‘£ğ‘–ğ‘–â„ + ğœ€ğœ€ğ‘–ğ‘–â„
Equation 7c is a logit model with a hospital-level random intercept (ğ›¼ğ›¼â„0 ) and a hospital-level random
coefficient on reperfusion (ğœ†ğœ†1 ğœƒğœƒâ„ + ğœğœâ„ ). In estimating Tables II-IV, we used a 2-step approach that first
estimated ğœƒğœƒâ„ from Equation 2, and then plugged this estimate into the survival equation. We now
estimate the treatment propensity equation (2) and the survival equation (7c) jointly, treating the
hospital-effect in the propensity equation (ğœƒğœƒâ„ ) and the hospital-level intercept (ğ›¼ğ›¼â„0 ) and coefficient on
reperfusion (ğœ†ğœ†1 ğœƒğœƒâ„ + ğœğœâ„ ) in the survival equation as jointly normal correlated random coefficients. The
remaining parameters determining the effect of reperfusion ( Î»0 , Î»1 ) were estimated along with the

variance and covariance of the hospital-level random coefficients by maximum likelihood. 13 Finally,


13
  To simplify estimation, we first estimated the coefficients on all of the covariates (X) in equations 2 and 7c
using simple logit models, and then used the estimated indices ( X ih Î²Ë† , X ih Î²Ë† 0 ) rather than the individual
covariates when estimating the random coefficient models. All the reported standard errors are conditional on



                                                                                                                                  29
knowledge of (ğœ†ğœ†1 ğœƒğœƒâ„ + ğœğœâ„ ), ğœ†ğœ†1 and ğœƒğœƒâ„ allows one to restate all of the estimates in terms of ğœğœâ„ rather
than (ğœ†ğœ†1 ğœƒğœƒâ„ + ğœğœâ„ ).
          We report the results from joint estimation of equation 2 and 7c in Table VII. We were reassured
that the more complicated joint estimation procedure replicates the results and magnitudes from simpler
models. For example, the coefficient on reperfusion from Table VII is 0.27 compared to 0.31 in the
simpler logit model in Table IV (both coefficients are in log-odds). The benefit of reperfusion increases
with the index with similar magnitudes in both modelsâ€”0.29 in Table IV vs. 0.28 from Table VII. The
threshold and general productivity are correlated -0.331 in the simpler model and are correlated -0.321
in the joint model, and both are estimated to have similar standard deviations using the simple and the
joint model. In particular, the joint model continues to estimate considerable variation across hospitals
in Ï„ h , the minimum threshold for treatment (Std. Dev. = 0.327). The consistency between the joint

estimates and simpler approaches reassures us that the estimates are not a consequence of the structure
that we have imposed. Consistent with the evidence presented in Table II, there is a negative correlation
(-0.341) between Ï„ h and the reperfusion intercept Î¸ h , suggesting that some of the variation in treatment

rates across hospitals is associated with variation in the treatment threshold (mostly overuse, as
suggested by Figures IV-V), but that this correlation is far from -1 (as would be the case if there was no
variation in comparative advantage) suggests that comparative advantage is also present.
         The joint estimation in Table VII yields estimates of the joint distribution of the hospital-level
parameters (ğœƒğœƒâ„ , ğ›¼ğ›¼â„0 , ğœğœâ„ ). However, our goal is to estimate the joint distribution of comparative advantage
(ğ›¼ğ›¼â„âˆ† ) and the treatment threshold (ğœğœâ„ ). Recall that ğœƒğœƒâ„ = ï¿½ğ›¼ğ›¼â„âˆ† âˆ’ ğœğœâ„ ï¿½/ğœğœğ‘£ğ‘£ , where ğœğœğ‘£ğ‘£ is the standard deviation
                                             Î”
of the patient-level idiosyncratic gains (ğ‘£ğ‘£ğ‘–ğ‘–â„ ), which we have so far ignored by assuming that it is one
(all our earlier results were invariant to this scaling). This implies that ğ›¼ğ›¼â„âˆ† = ğœğœâ„ + ğœğœğ‘£ğ‘£ ğœƒğœƒâ„ , so that the
distribution of comparative advantage (and its correlation with the treatment threshold) depends on both
ğœğœğ‘£ğ‘£ and the joint distribution of (ğœƒğœƒâ„ , ğœğœâ„ ). Therefore, it is important to know the scale factor in order to
make statements about comparative advantage. The scale parameter represents the standard deviation
of the unobservable factors determining expected benefit from treatment. While we cannot estimate it

directly, we used a range of values for ğœğœğ‘£ğ‘£ to calculate the standard deviation of Î± h and its correlation
                                                                                      âˆ†



with Ï„ h . These are presented in Appendix IV. Interestingly, these estimates bound the standard

deviation of Î± h to be above 0.3. Thus, our estimates imply that the variation across hospitals in
               âˆ†




the first-stage estimates X ih Î²Ë† , X ih Î²Ë† 0 , but any adjustment for using these generated regressors is likely to be
second-order because of the large samples used to estimate the patient-level coefficients.



                                                                                                                          30
comparative advantage is at least as large as the variation across hospitals in the treatment threshold
(SD=.327) and possibly much larger. For ğœğœğ‘£ğ‘£ < 1, corresponding to relatively less variation in
idiosyncratic differences across patients in the expected benefits from treatment, our estimates imply

similar amounts of variation in Ï„ h and Î± h , and that the two are strongly positively correlated (between
                                          âˆ†



0.4 and 1), meaning that hospitals with low comparative advantage tend to have low thresholds and
overuse reperfusion. Such a positive correlation (which was also noted above in Table VII) would arise
if all hospitals incorrectly believed that they had high comparative advantage in performing the
treatment, resulting in overuse among those hospitals that actually did not have a high comparative
advantage in performing the treatment (as we illustrated in Figure IIb). We examine this mechanism in
the next section.


                                            IV. MECHANISMS
    As noted earlier, there are two broad mechanisms that could lead to allocative inefficiency. First,
hospitals may be over-treating for financial gain (particularly in for-profit hospitals) or because of
benefits to future patients through learning-by-doing (particularly in teaching hospitals). This type of
mechanism would suggest that allocative inefficiency (Ï„) would be related to hospital characteristics
such as ownership, teaching status, etc. To investigate this hypothesis, we estimated the model from
Table IV adding interactions of treatment with a number of hospital-characteristics such as ownership,
teaching status and size (Table VIII). Overuse at for-profit hospitals or teaching hospitals, or at hospitals
with other characteristics that are included in the table, would mean that the return to treatment would
be lower at such facilities. The results demonstrate that there is no evidence that these characteristics are
associated with the return to treatment, conditional on the patientâ€™s propensity to receive treatment. A
joint-test on all the Treatment*Hospital Characteristics interactions canâ€™t reject the null-hypothesis that
these variables are jointly zero (chi-squared statistic=2.96; p-value=0.96). Yet, since overtreatment is
clearly in evidence from the earlier exhibits, we need another mechanism for why it happens. Note that
these hospital characteristics do predict variation in the use of reperfusion: for-profit hospitals and high-
volume hospitals were more likely to perform reperfusion, while teaching hospitals and hospitals that
treated high poverty populations were less likely to perform more reperfusion. The evidence in Table
VIII implies that differences across hospitals with these characteristics in reperfusion rates reflect
differences in comparative-advantage rather than differences in treatment thresholds.




                                                                                                          31
     A second mechanism for allocative inefficiency is that hospitals have imperfect information and
misperceive their comparative advantage, as we illustrated earlier in Figure IIb. 14 Given the general lack
of systematic performance feedback and small samples of their own treated patients to observe, it is
quite plausible that hospitals and physicians will have inaccurate beliefs about their own comparative
advantage. Put differently, there is no reason to think that physicians or hospitals know their ğ›¼ğ›¼â„âˆ†
perfectlyâ€”itâ€™s the difference of two parameters (ğ›¼ğ›¼â„0 ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ ğ›¼ğ›¼â„1 ) that are both measured with error. In this
mechanism, Î¸ represents a hospitalâ€™s belief about their comparative advantage and Ï„ represents a
hospitalâ€™s misperception (or prediction error) of their own comparative advantage.
     More formally, we can reinterpret our empirical model in the following way. Suppose that a hospital
does not know its comparative advantage, but instead has a belief about its comparative advantage which
is given by Î¸. Based on this belief, they treat patients if the expected benefit of treatment is positive.
                                                                     Î”
Thus, patients are treated based on beliefs (if ğœƒğœƒâ„ + ğ‘‹ğ‘‹ğ‘–ğ‘– ğ›½ğ›½ Î” + ğ‘£ğ‘£ğ‘–ğ‘–â„ > 0) rather than based on actual
                                                Î”
comparative advantage (if ğ›¼ğ›¼â„Î” + ğ‘‹ğ‘‹ğ‘–ğ‘– ğ›½ğ›½ Î” + ğ‘£ğ‘£ğ‘–ğ‘–â„ > 0). Let ğœğœâ„ represent the difference between a hospitalâ€™s
actual comparative advantage and their beliefs, so that ğœğœâ„ = ğ›¼ğ›¼â„Î” âˆ’ ğœƒğœƒâ„ is the hospitalâ€™s prediction error
(and therefore ğœƒğœƒâ„ = ğ›¼ğ›¼â„Î” âˆ’ ğœğœâ„ , as in our empirical model). Thus, this framework interprets ğœğœâ„ as arising
from an inaccurate belief about ğ›¼ğ›¼â„âˆ† , rather than assuming that hospitals know ğ›¼ğ›¼â„âˆ† and consciously set
ğœğœâ„ â‰ 0 to achieve other objectives. A negative ğœğœâ„ implies that the hospital over-estimated their
comparative advantage and, as a result, treated some patients who were in fact harmed by the treatment.
In this reframing, the key question is how hospitals form their beliefs.
     Suppose that each hospital receives a noisy signal of their comparative advantage (S), where
S=ğ›¼ğ›¼ Î” +Ï‰ and the noise (Ï‰) is independent of Î± with variance ğœğœÏ‰2 (we have suppressed the subscripts to
simplify notation). Based on this signal, the hospital forms a prediction of its comparative advantage
(Î¸). If the hospital knew the reliability of the signal (r=ğœğœğ›¼ğ›¼2 /(ğœğœğ›¼ğ›¼2 + ğœğœÏ‰2 ), where ğœğœğ›¼ğ›¼2 is the variance of ğ›¼ğ›¼ Î”
across hospitals), then the optimal prediction of ğ›¼ğ›¼ Î” given S is the posterior mean, given by E(ğ›¼ğ›¼ Î”
|S)=r*S. More generally, we assume that hospitals may not know the reliability of the signal, and form
their prediction using Î¸=w*S, where wâ‰ r. Incorrectly weighting the signal generates additional variation
in the prediction error (Ï„) which leads to greater allocative inefficiency. Even if hospital beliefs are
optimal given S (i.e., w=r), there will be allocative inefficiency (Ï„â‰ 0) because hospitals have imperfect
information, and this information only predicts a fraction (r) of the true variation in comparative
advantage.


14
 We are grateful to Janet Currie for suggesting this interpretation and alerting us to related work in Currie and
MacLeod (2017).



                                                                                                                   32
     This simple framework delivers a number of strong empirical implications. First, because the error
in the signal is assumed to be independent of the hospitalâ€™s actual productivity and comparative
advantage, this framework constrains the number of parameters in the structural model to six, which
allows us to identify the scale parameter and the variance in comparative advantage. More specifically,
our empirical model from Table VII estimated 6 reduced-form moments (the variances and covariances
of Î¸, Ï„, and Î±0) which are a function of the 6 unknown structural parameters in this framework (the
variances and covariance of ğ›¼ğ›¼ Î” and Î±0, the reliability of the signal r, the weight placed on the signal w,
and the scale parameter from the logit ğœğœğ‘£ğ‘£ ). 15 Therefore, we can derive estimates of the unknown
structural parameters for this model using minimum chi-squared estimation (Wooldridge 2010, p.442-
446). Minimum chi-squared estimation chooses the structural parameters that provide a best fit of the
reduced-form estimates (in a weighted least squares sense, using the standard errors & covariance of the
reduced form estimates to form weights). In the just-identified case the resulting structural parameters
fit the reduced form moments exactly because they are one-to-one function of the reduced form
parameters. These equations are derived and listed in Appendix V. Restrictions on the structural
parameters can be tested based on how they affect the structural models ability to fit the reduced form
estimates through a chi-squared goodness of fit statistic.
     Just-identified estimates of the structural parameters for this model are provided in the first column
of Table IX. There is substantial variation in comparative advantage (standard deviation of Î± = 0.317),
with the variation across hospitals being as large as the average treatment effect. The signal that hospitals
receive about their comparative advantage is estimated to have very low reliability (r=.065), but
hospitals place more weight on the signal than is optimal, with w=0.154.
     If w=r in this framework then beliefs are optimal. When we impose w=r (column 2 of Table IX),
we are over-identified (estimating 5 parameters from 6 moments) and can use the chi-squared goodness
of fit statistic to test the restriction (Wooldridge, 2010, pp. 444-445). This statistic rejects the hypothesis
that w=r (chi-squared with 1 df = 10.4, p=.001). In other words, the constrained model with w=r implies
reduced-form variances and correlations of Î¸, Ï„, and Î±0 that are significantly different from those
estimated in Table VII. More specifically, if w=r then the hospitalâ€™s prediction (Î¸) is optimal and,
therefore, should be uncorrelated with the prediction error (Ï„). The fact that we estimated a significant
negative correlation of -0.34 between Î¸ and Ï„ in Table VII implies that hospitalsâ€™ predictions are not
optimal and they are overweighting the noisy signal (w>r), i.e. they over-react to the signal. One might
not expect hospitals to have the information necessary to form optimal weights â€“ in particular, they may


15
  See Appendix V for derivation of the equations stating the reduced-form moments in terms of the structural
parameters.



                                                                                                               33
not know how much true variation in comparative advantage there is across hospitals, and are acting as
if they are using an over-diffuse prior (placing too much weight on their own signal, and not shrinking
enough to a prior mean).
       Finally, if hospitals learn based on their experience with patients, then one would expect that low-
volume hospitals would have less reliable signals of their comparative advantage than high-volume
hospitals. In the third column of Table IX we fit our model to reduced-form moments estimated
separately for low, medium and high-volume hospitals (6 moments for each group, for a total of 18
moments), allowing the reliability parameter to vary across the 3 groups but otherwise constraining the
remaining model parameters to be equal across the 3 groups (8 parameters total to fit 18 moments). As
expected, the reliability of the signal is estimated to be highest for the high-volume hospitals and lowest
for the low-volume hospitals. Moreover, the goodness of fit statistic cannot reject our model (chi-
squared with 10 df = 12.7, p=.24) suggesting that this simple model provides an adequate fit of the data.
In other words, the model estimated in column 3 of Table IX implies reduced-form variances and
correlations of Î¸, Ï„, and Î±0 that are not significantly different from the unconstrained reduced-form
estimates for low, medium, and high-volume hospitals. Assuming that reliability of the signal is the
same for high, medium and low-volume hospitals (final column of Table IX) is strongly rejected (chi-
squared with 2 df = 49.7, p<.0001) and such a model is strongly rejected by the goodness-of-fit test (chi-
squared with 12 df = 62.4, p<.0001).


                                                        V. WELFARE IMPLICATIONS
           We can use our results to construct a stylized estimate of the welfare loss generated by this
allocative inefficiency, along the lines suggested by Phelps (2000). Returning to the intuition from
Figure IIb, a patient in a hospital which uses a Ï„ that is different than zero experience a welfare loss,
where:
                                                â„ğ‘’ğ‘’ğ‘’ğ‘’ğ‘’ğ‘’â„ğ‘¡ğ‘¡             ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘

           ğ‘Šğ‘Šğ‘Šğ‘Šğ‘Šğ‘Šğ‘Šğ‘Šğ‘Šğ‘Šğ‘Šğ‘Šğ‘Šğ‘Š ğ¿ğ¿ğ¿ğ¿ğ¿ğ¿ğ¿ğ¿ğ‘–ğ‘–â„ =
                                          1
                                            .    ï¿½) ï¿½ï¿½
                                                 (ğœğœ
                                                          ï¿½ï¿½ğ‘‘ğ‘‘ğ‘‘ğ‘‘ğ‘‘ğ‘‘(ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡
                                                             ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½              ğ‘–ğ‘–â„ )
(8a)
                                          2         â„ (ğœğœâ„ )                  dğœğœ

The welfare loss due to allocative inefficiency is the average reduction in (logodds) survival per
                                                                                                      ğ‘‘ğ‘‘ğ‘‘ğ‘‘ğ‘‘ğ‘‘(ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡)
patient. 16 Noting that ğ¸ğ¸(ğœğœâ„ 2 ) = ğ‘‰ğ‘‰ğ‘‰ğ‘‰ğ‘‰ğ‘‰(ğœğœâ„ ) + [ğ¸ğ¸(ğœğœâ„ )]2 , and letting                                                      represent the average
                                                                                                                 dğœğœ

effect of a change in ğœğœâ„ across all patients, the average welfare loss across all hospitals is given by:
                                                  1                ğ‘‘ğ‘‘ğ‘‘ğ‘‘ğ‘‘ğ‘‘(ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡)     1                  ğ‘‘ğ‘‘ğ‘‘ğ‘‘ğ‘‘ğ‘‘(ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡)
(8b)       ğ¸ğ¸(ğ‘Šğ‘Šğ‘Šğ‘Šğ‘Šğ‘Šğ‘Šğ‘Šğ‘Šğ‘Šğ‘Šğ‘Šğ‘Šğ‘Š ğ¿ğ¿ğ¿ğ¿ğ¿ğ¿ğ¿ğ¿ğ‘–ğ‘–â„ ) = . ğ‘‰ğ‘‰ğ‘ğ‘ğ‘ğ‘(ğœğœâ„ )                                     + . [ğ¸ğ¸(ğœğœâ„ )]2
                                                  2                           dğœğœ                 2                             dğœğœ



16
  The welfare loss is measured in the same units as Ï„ (logodds of survival in our estimates) and is the welfare
loss per patient because we use the probability of treatment rather than total number treated.



                                                                                                                                                     34
The welfare loss can be broken into two parts â€“ the first due to variance in ğœğœâ„ and the second due to
systematic bias in ğœğœâ„ , across all hospitals. We estimate each in turn.
       For the first term, we can return to the hierarchical-logit model in Table VII, where we estimated
ğ‘†ğ‘†ğ‘†ğ‘†(ğœğœâ„ )=0.327. 17 To get an estimate of ğ‘‘ğ‘‘ğ‘‘ğ‘‘ğ‘‘ğ‘‘(ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡)â„ğ‘‘ğ‘‘ğ‘‘ğ‘‘, which is a change in the propensity to
receive treatment for a small increase in Ï„, we took a tiny change of 0.01 in ğœğœâ„ , divided it by our estimate
of the scale factor (ğœğœğ‘£ğ‘£ ) of 0.44 to turn it into how much change that would create in the hospitals risk-
adjusted treatment rate ğœƒğœƒâ„ . Adding this change in ğœƒğœƒâ„ to each patientâ€™s propensity index yielded an
estimate of the average effect across all patients of ğ‘‘ğ‘‘ğ‘‘ğ‘‘ğ‘‘ğ‘‘(ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡)â„ğ‘‘ğ‘‘ğ‘‘ğ‘‘ =-0.26. So the welfare loss
from variation in allocative inefficiency is (1/2)*(0.327^2)*(-0.26)= -0.014, i.e. the allocative
inefficiency across hospitals results in an average reduction in the logodds of survival per patient of
.014. The overall benefit from treatment is the benefit among the treated (0.265 in log-odds for the
average treated patient from Table VII), who comprise 19 percent of the patient population for a total
average benefit of 0.05. This means that we could increase the effectiveness of treatment by about 28%
(.014/.05) if we removed the allocative inefficiency across hospitals.
       The second term of the welfare loss equation says that there is additional welfare loss if there is
systematic overuse across all hospitals, i.e. if the mean of Ï„ is not equal to zero. This part of the welfare
calculation is more speculative. A good guess about systematic overuse across all hospitals comes from
the average treatment effect among patients with very low propensity, since the treatment effect
asymptotes at ğœğœâ„ as the propensity goes to zero in the limit. In Figure IV, patients with the lowest
propensity being plotted (with about a 5% chance of treatment) have an average treatment effect of
roughly -0.25 (a bit higher for conservative hospitals, a bit lower for aggressive hospitals), suggesting
that ğ¸ğ¸(ğœğœâ„ ) < âˆ’0.25. Therefore, the additional welfare loss from systematic overuse should be at least
(1/2)*(-0.25^2)*(-0.26)=-0.008, which would raise the overall loss from .014 (28% ) to .022 (44%). This
calculation suggests that systematic overuse adds substantially to the welfare loss from the overall
variation.
       Put differently, these estimates mean that a policy which provided better information about
treatment effect heterogeneity across hospitals could improve patient welfare by reducing the prediction
error ğœğœâ„ , where ğœğœâ„ = ğ›¼ğ›¼â„Î” âˆ’ ğœƒğœƒâ„ . Our more structural estimates from Table IX suggest that it is very
difficult for hospitals to predict their own comparative advantage â€“ they receive very unreliable signals,
and then overweight these noisy signals. But if all hospitals had perfect information about ğ›¼ğ›¼â„Î” , and acted
on it, we would eliminate allocative inefficiency entirely and improve the average value of the treatment


17
     The simpler model in Table 4 yielded a very similar estimate of 0.31.



                                                                                                               35
by 44% (based on the calculation above, assuming perfect information eliminates both the bias and
variation in ğœğœâ„ ).
    Our estimates also allow us to consider other counterfactuals. One alternative counterfactual would
be to encourage more complete standardization in treatment rates across hospitals, along the lines often
suggested by policy makers concerned about unwarranted variation across hospitals in treatment rates.
In our model, this is equivalent to getting hospitals to ignore the signal (S) about their own comparative
advantage, and instead all use a common ğœƒğœƒ as an estimate of their own comparative advantage. Policy-
makers often have the sense that ğœƒğœƒ should be set to the average true comparative-advantage. The main
benefit from this type of standardization is it can potentially eliminate the welfare loss from systematic
bias in ğœğœâ„ . As we calculated above, eliminating this bias improves welfare by at least 16%. But there is
also a cost from this type of standardization as it ignores true differences across hospitals in comparative
advantage, and through this channel, increases allocative inefficiency. If hospitals were perfectly
predicting the variation in ğ›¼ğ›¼â„Î” (so that ğœğœâ„ = 0), then standardization would lead to greater prediction
errors resulting in ğ‘‰ğ‘‰ğ‘‰ğ‘‰ğ‘‰ğ‘‰(ğœğœâ„ ) = ğ‘‰ğ‘‰ğ‘‰ğ‘‰ğ‘‰ğ‘‰ï¿½ğ›¼ğ›¼â„Î” ï¿½. Using the estimate of the standard deviation of ğ›¼ğ›¼â„Î” from Table
IX (0.317), we estimate that the welfare loss from standardization (relative to the first best of perfect
prediction of ğ›¼ğ›¼â„Î” ) is (1/2)*(0.317^2)*(-0.26)=-0.013. Note that this is similar to the welfare loss from
variation in ğœğœâ„ under current practice (-.014) because hospitals are doing such a poor job of predicting
their own comparative advantage. Thus, in this case, there is no cost (relative to current practice) from
reducing variation in treatment rates across hospitals and some benefit if standardization were able to
remove the overall bias toward over-treatment.
    A third, perhaps more realistic, counterfactual would be to encourage more standardization in
treatment rates across patients. One possibility would be just prohibiting hospitals from treating patients
below a certain cutoff and giving hospitals discretion in treating patients above the cutoff. This is similar
to having evidence-based guidelines, and discouraging hospitals from treating outside of guidelines.
Note that if there were no systematic bias toward over-treatment (i.e., ğ¸ğ¸(ğœğœâ„ ) = 0) then there would be
no benefit from this strategy. If there were no bias then even low propensity patients would, on average,
have positive treatment effects on the treated (although there would be negative treatment effects in
some hospitals). Thus, this strategy is a second-best solution to the bias problem â€“ rather than eliminating
the bias (which benefits all patients), we eliminate treatment for low-propensity patients who are most
negatively affected by the bias toward over-treatment. To calculate how much would be gained from
this strategy, we compared the existing average benefit from treatment (.050) to a counterfactual in
which we set treatment to 0 for all patients for whom the ğœ†ğœ†0 + ğœ†ğœ†1 âˆ— ğ‘‹ğ‘‹ğ‘–ğ‘– ğ›½ğ›½ < 0, using estimates of the
treatment effect on the treated for these patients (including the hospital random effects) derived from



                                                                                                              36
the model in Table VII. Just over 18% of patients currently getting the treatment are predicted to have
negative treatment effects, and not treating these patients increases the average benefit across all patients
by 14% to .057. The gains from this second-best approach (.007) are nearly as large as the gains we
estimated from eliminating bias (.008), suggesting once again that systematic overuse is a central
component of welfare losses.


                                            VI. CONCLUSION
    Using a Roy model of treatment to motivate our empirical framework, we found significant evidence
of allocative inefficiency across hospitals. In addition to the welfare loss from allocative inefficiency,
we also found evidence of substantial variation in comparative advantage across hospitals, with the
benefits from treatment being much higher in some hospitals than others. This variation in the benefits
from treatment implies that â€œone size fits allâ€ policies such as strict treatment guidelines are incorrect,
since hospitals with greater comparative advantage at a treatment should use it more among their
patients. Moreover, our evidence suggests that much of the allocative inefficiency that we observe is
due to hospitals having imperfect information and misperceiving their comparative advantage. This is a
different mechanism than explaining variations by appealing to medical malpractice or financial
entrepreneurship by providers (Gawande, 2009). Thus, rather than reducing treatment variation across
hospitals, better information about treatment effect heterogeneity across hospitals is key to improving
patient welfare. We donâ€™t know if these findings and conclusions generalize to settings beyond the
treatment of heart attack patients, but our framework is general and can be applied to a variety of settings.
    Our work suggests three new directions for research on productivity in healthcare. By uniting the
literatures from economics and medicine on variations in medical care with insights from the
productivity literature, we found that variation in comparative advantage (productive efficiency) plays
an important role in generating treatment variation. Thus, future work should explore sources of
variation in productive efficiency across hospitals and broaden the idea of productive efficiency beyond
simple TFP (Garber and Skinner, 2008) to consider the reasons for comparative advantage in particular
types of care. By separately identifying allocative inefficiency, we also found that lack of information
about the variation across hospitals in comparative advantage generates substantial welfare loss. This
finding is similar to Abaluck et al. (2016), who find that physician misperceptions about which patients
benefit most from testing generate substantial welfare loss. Thus, future work should also explore how
patients and providers learn about and respond to variation in productive efficiency. This would involve
taking our framework for understanding how hospitals differ in efficiency, and combining it with the
insights in Hull (2018), which finds evidence that patients select on gains in terms of choosing hospitals.




                                                                                                          37
    Our framework can also be applied to a range of related puzzles such as the presence of racial and
gender disparities in treatment and the slow diffusion of new treatments that were proven effective in
randomized trials (Chandra and Staiger, 2010). As with the variation we study across hospitals, our
framework can identify the underlying source of these differences in treatment across populations. Our
findings suggest that misperceptions and learning about the heterogeneous benefits of treatment across
hospitals and patients may play a key role in understanding all of these puzzles.
    Finally, and related to the point about heterogeneous benefits, our works speaks to using more
economic structure at the time of estimating simpler reduced-form estimates of the marginal value of
health. Regression-discontinuity designs such as those involving birthweight cuts are recovering the
average marginal effect of a treatment across all hospitals and all patients. These approaches often focus
on removing a demand-side confounder like patient illness. The Roy-model approach notes that there is
substantial heterogeneity in the treatment effect across hospitals and across patients, with the marginal
effect of more treatment depending on which patient receives the treatment, and which hospital delivers
it. These are supply-side explanations, and ignoring such heterogeneity, across patients and hospitals,
creates problems for the interpretation of simpler approaches.
    But RCTs and other approaches can also be deployed to test other implications of our model, and
we believe that a greater use of these methods to test approaches like ours is central. These methods
could be deployed to test selection on gainsâ€”perhaps by evaluating whether the average treatment effect
is smaller than treatment on the treated. One setting to validate our paper would be one where it became
slightly harder to access treatment in a hospital. We would predict that the extra costs would reduce
treatment for the marginal patient, and that this marginal patient will be different in different hospitals:
in more intensive hospitals (as measured by risk-adjusted treatment rates), the marginal patient will be
less appropriate in the global distribution of patient characteristics. Another test would be to give
hospitals more information about their comparative-advantage and see if this information is used by
hospitals to change their treatment decisions. Our model would predict that if hospitals respond to their
information then (1) some less appropriate patients will no longer be treated (2) overall outcomes will
improve and that this will be driven by a lack of overuse in less appropriate patients, and (3) these effects
will be concentrated in smaller hospitals. These insights flow from a Roy model of treatment allocation,
but not from theory-agnostic approaches that measure average treatment effects across all patients and
hospitals.


HARVARD UNIVERSITY AND THE NBER
DARTMOUTH COLLEGE AND THE NBER




                                                                                                          38
                                           REFERENCES
Abaluck, Jason, Leila Agha, Chris Kabrhel, Ali Raja, and Arjun Venkatesh. "The Determinants of
       Productivity in Medical Testing: Intensity and Allocation of Care." American Economic
       Review 106, no. 12 (2016): 3730-64.
Baicker, Katherine, Amitabh Chandra, and Jonathan S. Skinner. "Saving Money or Just Saving Lives?
        Improving the Productivity of US Health Care Spending." Annual Review of Economics 4, no.
        1 (2012): 33-56.
Barnato, Amber E., F. Lee Lucas, Douglas Staiger, David E. Wennberg, and Amitabh Chandra.
       "Hospital-Level Racial Disparities in Acute Myocardial Infarction Treatment and
       Outcomes." Medical Care 43, no. 4 (2005): 308.
Burstein, Harold J., Christina Lacchetti, Holly Anderson, Thomas A. Buchholz, Nancy E. Davidson,
        Karen A. Gelmon, Sharon H. Giordano et al. "Adjuvant Endocrine Therapy for Women With
        Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused
        Update." J Clin Oncol 37, no. 5 (2018): 423-438.
Chandra, Amitabh, Amy Finkelstein, Adam Sacarny, and Chad Syverson. "Productivity Dispersion in
       Medicine and Manufacturing." American Economic Review 106, no. 5 (2016): 99-103.
â€”â€” "Health Care exceptionalism? Performance and Allocation in the US Health Care
     Sector." American Economic Review 106, no. 8 (2016): 2110-44.
Chandra, Amitabh, and Douglas O. Staiger. "Productivity Spillovers in Health Care: Evidence from
       the Treatment of Heart Attacks." Journal of Political Economy 115, no. 1 (2007): 103-140.
â€”â€” Identifying Provider Prejudice in Healthcare. No. w16382. National Bureau of Economic
     Research, 2010.
Chandra, Amitabh, and Jonathan Skinner. "Technology Growth and Expenditure Growth in Health
       Care." Journal of Economic Literature 50, no. 3 (2012): 645-80.
Currie, Janet, and W. Bentley MacLeod. "Diagnosing Expertise: Human Capital, Decision Making,
         and Performance Among Physicians." Journal of Labor Economics 35, no. 1 (2017): 1-43.
Doyle, Joseph J. "Returns to Local-Area Health Care Spending: Evidence from Health Shocks to
        Patients Far from Home." American Economic Journal: Applied Economics 3, no. 3 (2011):
        221-43.
Doyle Jr, Joseph J., John A. Graves, Jonathan Gruber, and Samuel A. Kleiner. "Measuring Returns to
        Hospital Care: Evidence from Ambulance Referral Patterns." Journal of Political
        Economy 123, no. 1 (2015): 170-214.
Finkelstein, Amy, Matthew Gentzkow, and Heidi Williams. "Sources of Geographic Variation in
        Health Care: Evidence from Patient Migration." Quarterly Journal of Economics 131, no. 4
        (2016): 1681-1726.
Fibrinolytic Therapy Trialistsâ€™ Collaborative Group. "Indications for Fibrinolytic Therapy in
        Suspected Acute Myocardial Infarction: Collaborative Overview of Early Mortality and Major
        Morbidity Results from All Randomised Trials of More Than 1000 Patients." The Lancet 343,
        no. 8893 (1994): 311-322.
Fisher, Elliott S., David E. Wennberg, Thrse A. Stukel, Daniel J. Gottlieb, F. Lee Lucas, and Etoile L.
        Pinder. "The Implications of Regional Variations in Medicare Spending. Part 1: The Content,



                                                                                                     39
        Quality, and Accessibility of Care." Annals of Internal Medicine 138, no. 4 (2003a): 273-287.
â€”â€” "The Implications of Regional Variations in Medicare Spending. Part 2: Health Outcomes and
     Satisfaction with Care." Annals of Internal Medicine 138, no. 4 (2003b): 288-298.
Garber, Alan M., and Jonathan Skinner. "Is American Health Care Uniquely Inefficient?" Journal of
        Economic Perspectives 22, no. 4 (2008): 27-50.
Gawande, Atul. "The Cost Conundrum." The New Yorker 1 (2009): 36-44.
Heckman, James J., Sergio Urzua, and Edward Vytlacil. "Understanding Instrumental Variables in
      Models with Essential Heterogeneity." The Review of Economics and Statistics 88, no. 3
      (2006): 389-432.
Hull, Peter. "Estimating Hospital Quality with Quasi-Experimental Data." Available at SSRN
        3118358 (2018).
Marciniak, Thomas A., Edward F. Ellerbeck, Martha J. Radford, Timothy F. Kresowik, Jay A. Gold,
       Harlan M. Krumholz, Catarina I. Kiefe, Richard M. Allman, Robert A. Vogel, and Stephen F.
       Jencks. "Improving the Quality of Care for Medicare Patients with Acute Myocardial
       Infarction: Results from the Cooperative Cardiovascular Project." Journal of the American
       Medical Association 279, no. 17 (1998): 1351-1357.
McClellan, Mark, Barbara J. McNeil, and Joseph P. Newhouse. "Does More Intensive Treatment of
       Acute Myocardial Infarction in the Elderly Reduce Mortality?: Analysis Using Instrumental
       Variables." Journal of the American Medical Association 272, no. 11 (1994): 859-866.
O'Connor, Gerald T., Hebe B. Quinton, Neal D. Traven, Lawrence D. Ramunno, T. Andrew Dodds,
      Thomas A. Marciniak, and John E. Wennberg. "Geographic Variation in the Treatment of
      Acute Myocardial Infarction: The Cooperative Cardiovascular Project." Journal of the
      American Medical Association 281, no. 7 (1999): 627-633.
O'Gara, Patrick T., Frederick G. Kushner, Deborah D. Ascheim, Donald E. Casey, Mina K. Chung,
        James A. De Lemos, Steven M. Ettinger et al. "2013 ACCF/AHA Guideline for the
        Management of ST-Elevation Myocardial Infarction: A Report of the American College of
        Cardiology Foundation/American Heart Association Task Force on Practice
        Guidelines." Journal of the American College of Cardiology 61, no. 4 (2013): e78-e140.
Phelps, Charles E. "Information Diffusion and Best Practice Adoption." In Handbook of Health
        Economics, vol. 1, pp. 223-264. Elsevier, 2000.
Skinner, Jonathan. "Causes and Consequences of Regional Variations in Health Care." In Handbook of
        Health Economics, vol. 2, pp. 45-93. Elsevier, 2011.
Skinner, Jonathan, Douglas Staiger. "Technology Diffusion and Productivity Growth in Health Care,"
        Review of Economics and Statistics 97, no.5 (2015): 951-964.
Suri, Tavneet. "Selection and Comparative Advantage in Technology Adoption." Econometrica 79,
        no. 1 (2011): 159-209.
Syverson, Chad. "What Determines Productivity?" Journal of Economic Literature 49, no. 2 (2011):
       326-65.
Yasaitis, Laura, Elliott S. Fisher, Jonathan S. Skinner, and Amitabh Chandra. "Hospital Quality and
        Intensity of Spending: Is There an Association?" Health Affairs 28, no. 4 (2009): w566-w572.
Wooldridge, Jeffrey M. Econometric Analysis of Cross Section and Panel Data. MIT press, 2002.




                                                                                                    40
                                            .6
                    Hospital treatment effect from survival logit
                            0           .2  -.2       .4




                                                                          -1                  -.5              0               .5                  1
                                                                                              Hospital intercept from propensity logit


                                                                                                        FIGURE I
                                                                                    Motivating Facts from the CCP Data
                                                                                                        PANEL A
Survival benefit associated with reperfusion versus risk-adjusted rate of reperfusion at the hospital
                      level (correlation = -0.02, Number of hospitals =4690)
                                                          .8
                                   Probability of receiving reperfusion
                                       .2            .4   0     .6




                                                                               -2                   -1                  0                      1
                                                                                    Treatment propensity index based on patient characteristics

                                                                                      Hospitals in lowest tercile           Hospitals in highest tercile




                                                                                                        FIGURE I
                                                                                    Motivating Facts from the CCP Data
                                                                                                        PANEL B
Probability of Receiving Reperfusion According to Patient Characteristics and Hospital Treatment
                                           Intensity



                                                                                                                                                           41
                      Effect of reperfusion on logodds of 30-day survival
                       -.5       -.25      0       .25      .5       .75




                                                                            -2                   -1                   0                      1
                                                                                 Treatment propensity index based on patient characteristics

                                                                                   Hospitals in lowest tercile           Hospitals in highest tercile




                                                                                                     FIGURE I
                                                                                 Motivating Facts from the CCP Data
                                                                                                     PANEL C
   Survival Benefit Associated with Reperfusion According to Patient Characteristics and Hospital
                                       Treatment Intensity


        In Panel A, the risk-adjusted rate of reperfusion at the hospital level is an empirical Bayes
estimate of the hospital-level intercept from a random-effect logit model of whether a patient received
reperfusion within 12 hours regressed on a rich set of covariates derived from patient charts (see
Appendix I for a full list) and a hospital-level random intercept. The survival benefit associated with
reperfusion is an empirical Bayes estimate of the hospital-level coefficient on reperfusion from a
random-coefficient logit model of whether a patient survived 30 days after their heart attack regressed
on whether the patient received reperfusion within 12 hours, controlling for the full set of patient
covariates, and allowing for a hospital-level random intercept and (possibly correlated) random
coefficient on reperfusion.

        In Panel B, we non-parametrically plot the probability of treatment as a function of the
treatment propensity index from the reperfusion logit based on patient covariates (without the hospital
intercept), estimating separate lines for the probability of treatment in hospitals in the highest (most
aggressive) and lowest (most conservative) terciles of risk-adjusted treatment rates (the hospital-level
reperfusion intercept).

         In Panel C, we non-parametrically plot the effect of reperfusion on survival as a function of
the treatment propensity index based on patient characteristics (without the hospital intercept),
separately for hospitals in the highest (most aggressive) and lowest (most conservative) terciles of
risk-adjusted treatment rates. The survival benefit at each point in the distribution of the propensity
index was estimated flexibly using a local-logistic regression of 30-day survival on reperfusion that
controlled for the detailed risk adjusters available in the CCP. The lines in Panels B and C are based
on local regressions with a triangular kernel that included 30% of the sample on either side.

All estimates are based on data from the CCP for 138,957 AMI patients treated in 4690 hospitals.



                                                                                                                                                        42
                                              FIGURE IIa
                              A Roy Model of Treatment at the Hospital Level

           The two lines denote patient survival if a hospital treats a given patient with usual care (intercept
is ğ›¼ğ›¼â„0 ) or with reperfusion treatment (intercept is ğ›¼ğ›¼â„1 ) as a function of patient characteristics (i.e. patient
Xâ€™s) on the x-axis. We have suppressed the distribution of unobservables that come out of the plane.
Expertise at usual care and reperfusion is captured by the intercepts ğ›¼ğ›¼â„0 and ğ›¼ğ›¼â„1 respectively, with
comparative advantage being the difference between them. Allocative efficiency means that reperfusion
should be performed to the point that the marginal patient receiving it receives zero benefit (Ï„h = 0).




                                                                                                                43
                                          FIGURE IIb
            A Roy Model of Treatment at the Hospital Level with Allocative Inefficiency

        The figure illustrates the presence of allocative inefficiency. Here, misperceptions about
comparative advantage at delivering the treatment result in more patients treated than is optimal. It is
also possible that some hospitals overuse treatment because of maximizing something other than
survival, rather than because of misperceptions about comparative advantage. As drawn, the hospital
overuses treatment and uses a negative threshold (Ï„h). The shaded triangle represents the welfare loss.




                                                                                                      44
                                                  FIGURE III
           Distinguishing Underuse and Overuse Using the Propensity to Receive Treatment

The figure illustrates the relationship between the expected benefit from treatment, E (Yihâˆ† | Yihâˆ† > Ï„ h ), on the
  vertical axis, and the propensity index I on the horizontal axis. The propensity to receive treatment
   depends on patient characteristics and a hospitals assessment of its hospital specific benefit from
   treatment. The curves represent the treatment-on-the-treated effect for a patient with index I, and
approach the minimum threshold (Ï„) for a patient with a low propensity of being treated. The top curve
  represents a hospital with a high treatment threshold (underuse) and the bottom curve represents a
                            hospital with a low treatment threshold (overuse).




                                                                                                                45
                                           FIGURE IV
                Survival Benefit from Reperfusion by Patientâ€™s Treatment Propensity,
               Low-Treatment-Rate (Left) and High-Treatment-Rate (Right) Hospitals.

        The figures plot the estimated survival benefit (and 95% confidence intervals) from reperfusion
against a patientâ€™s treatment propensity index for hospitals in the lowest (left-hand side) and highest
(right-hand side) terciles of the estimated hospital effect from the propensity equation. Propensity
Equation is Pr(Reperfusion)=F(Xb+ Hospital Effect) and is estimated using a logit model; see Appendix
II. Propensity index refers to the logit index (XB+Hospital Effect). It is demeaned to the average value
of patients receiving reperfusion. All models include all CCP risk-adjusters.




                                                                                                     46
                                              FIGURE V
            Survival Benefit from Reperfusion by Risk-Adjusted Hospital Treatment Rate,
                       All Patients (Left) and Low-Propensity Patients (Right)

         The left-hand panel plots the estimated survival benefit from reperfusion (and 95% confidence
interval) against the hospital effect from the propensity equation using a locally-weighted logit model
to estimate the reperfusion effect (controlling non-parametrically for the propensity index as was done
in column 3 of Table 2). The right-hand panel is the analogous plot estimated only for low-propensity
patients whose propensity index implied that they had below a 20% probability of receiving reperfusion.
Propensity Equation is Pr(Reperfusion)=F(Xb+ Hospital Effect) and is estimated using a logit model;
see Appendix II. Propensity index refers to the logit index (XB+Hospital Effect). It is demeaned to the
average value of patients receiving reperfusion. All models include all CCP risk-adjusters.




                                                                                                    47
             TABLE I: Patient Characteristics, Full Sample and by Reperfusion

 Variable                                      Full           Received                No
                                              Sample        Reperfusion          Reperfusion
                                                            w/in 12 hours        w/in 12 hours

 Survival 30 days post-AMI                     81%              86%                  80%
 Reperfusion within 12 hours                   19%             100%                   0%
 Age (in years)                                76.7             73.5                 77.4
 Female (percent)                              49.5             43.2                 50.9
 Black (percent)                                5.9              4.0                  6.4

 Previous diagnoses:
   Congestive Heart Failure                    22%              7%                   25%
   Hypertension                                62%              56%                  63%
   Diabetes                                    30%              23%                  32%
   Dementia                                     6%              2%                    7%

 Percent treated at Non-Profit Hospital         19.6             20.7                19.3
 Percent treated at For-Profit Hospital         10.6             11.0                10.5
 Percent treated at Government Hospital         13.2             12.7                13.4
 Percent treated at Major Teaching              20.2             20.5                18.7
 Percent treated at Minor Teaching              14.3             14.1                14.2
 Number of Beds at Treating Hospital           275.3            274.6                275.5

 Number of observations                      138,957           25,876              113,081



Note: Sample is from the Cooperative Cardiovascular Project (CCP), which included data derived
from patient charts for all Medicare beneficiaries with acute myocardial infarction admitted during
selected months during 1994 and 1995. There are 4,690 hospitals in the sample. Full-list of variables
and additional detail on the sample and data collection is in Appendix I.




                                                                                                        48
                 TABLE II: Effect of Reperfusion on 30-day Survival, OLS and Logit Estimates

                                     OLS        OLS         OLS         OLS         Logit     Logit           Logit
                                      (1)        (2)         (3)         (4)         (5)        (6)            (7)

   Reperfusion                       0.039      0.043       0.044                   0.328      0.344
                                    (0.003)    (0.003)     (0.003)                 (0.027)    (0.027)

   Reperfusion*Propensity index      0.040      0.042                               0.291
                                    (0.002)    (0.002)                             (0.018)

   Reperfusion* Hospital Rate (Î¸)               -0.031     -0.037       -0.037     -0.211       -0.251         -0.252
                                                (0.009)    (0.009)       (0.009)   (0.076)     (0.076)        (0.077)


   Hospital Fixed-Effects            Yes         Yes        Yes          Yes         Yes        Yes           Yes

                                                            Mills       Non-                   Mills        Non-
   Control for Propensity Index      None       Linear      Ratio     Parametric    Linear     Ratio      Parametric



Note: Dependent variable is whether patient survived to 30 days. Reperfusion measures receipt of reperfusion therapy
within 12 hours of admission. OLS coefficients are percentage-point changes in survial and logit coefficients are log-
odds. Propensity Equation is Pr(Reperfusion)=F(Xb+ Hospital Effect) and is estimated using a logit model; see
Appendix II. Propensity index refers to the logit index (XB+Hospital Effect). It is demeaned to the average value of
patients receiving reperfusion. All models include all CCP risk-adjusters. Columns 2 and 5 include linear controls for
propensity-index. Columns 3 and 6 use a mills-ratio but retain OLS/Logit for the survival equation for comparability.
Columns 4 and 7 include 100 percentiles of propensity-index interacted with the receipt of Reperfusion. Sample-size in
every regression is 138,957.




                                                                                                         49
      TABLE III: Effect of Reperfusion on 7-day and 365-day Survival, Logit Estimates

                                                             Conditional           Conditional
                                                            on Propensity         on Propensity

                                                                  (1)                   (2)
Panel A: 7 Day Survival

  Reperfusion                                                   0.218             non-parametric
                                                               (0.031)

  Reperfusion * Propensity index                                0.356             non-parametric
                                                               (0.021)

  Reperfusion * Hospital Treatment Rate (Î¸)                     -0.271                -0.325
                                                               (0.087)                (0.088)

   Control for Propensity Index                                 Linear            Non-Parametric

Panel B: 365 Day Survival

  Reperfusion                                                   0.393             non-parametric
                                                               (0.023)

  Reperfusion * Propensity index                                0.176             non-parametric
                                                               (0.017)

  Reperfusion * Hospital Treatment Rate (Î¸)                     -0.147                -0.192
                                                               (0.066)                (0.067)

   Control for Propensity Index                                 Linear            Non-Parametric


Note: Coefficients are log-odds. Table is analogous to Table 2. Propensity Equation is
Pr(Reperfusion)=F(Xb+ Hospital Effect) and is estimated using a logit model; see Appendix II.
Propensity index refers to the logit index (XB+Hospital Effect). It is demeaned to the average value
of patients receiving reperfusion. Column 1 reports equation 7a and Column 2 reports equation 7b.
All models include all CCP risk-adjusters. Sample-size in every regression is 138,957.




                                                                                                   50
        TABLE IV: Effect of Reperfusion on 30-day Survival, Mixed-Logit Estimates

                                                                               (1)          (2)
Reperfusion                                                                   0.297        0.314
                                                                             (0.022)      (0.024)

Reperfusion*Propensity index                                                  0.289        0.292
                                                                             (0.017)      (0.017)


Std dev of hospital intercept (Î±0)                                            0.188        0.198
                                                                             (0.015)      (0.017)

Hospital Level Random-Intercept (Î±0)                                           Yes         Yes
Hospital Level Random Coefficient on Reperfusion (Ï„)                           No          Yes

Std dev of hospital coefficient on reperfusion                                             0.313
(identifies Ï„; hospital level thresholds)                                                 (0.056)

corr(hospital level intercept, coefficient on reperfusion)                                -0.331
(identifies corr (Î±0, Ï„))                                                                 (0.154)

Number of Hospitals                                                           4,690        4,690


Note: Coefficients are log-odds. Propensity Equation is Pr(Reperfusion)=F(Xb+ Hospital Effect)
and is estimated using a logit model; see Appendix II. Propensity index refers to the logit index
(XB+Hospital Effect). It is demeaned to the average value of patients receiving reperfusion. Table
reports estimating Equation 6a. All models include all CCP risk-adjusters. Sample-size in every
regression is 138,957.




                                                                                                     51
     TABLE V: Testing for violations of the Single-Index Assumption, Logit Estimates

                                                              Hospital Characteristic

                                                   Hospital       Ln (Volume)            Major
                                                  Treatment                             Teaching
                                                    Rate                                Hospital

Reperfusion                                         0.330            0.178               0.296
                                                   (0.027)          (0.118)             (0.027)

Reperfusion * Index                                 0.295            0.289               0.268
                                                   (0.021)          (0.088)             (0.020)

Reperfusion * Hospital Treatment Rate              -0.216
                                                   (0.077)

Reperfusion * Hospital Treatment Rate *            -0.019
Index                                              (0.056)

Reperfusion * ln (Volume)                                            0.031
                                                                    (0.029)

Reperfusion * ln (Volume) * Index                                   -0.001
                                                                    (0.022)

Reperfusion * Major Teaching Hospital                                                    0.026
                                                                                        (0.058)

Reperfusion * Major Teaching Hospital*                                                   0.086
Index                                                                                   (0.044)

Control for Propensity Index                    Linear           Linear            Linear

Note: Coefficients are log-odds. Propensity Equation is Pr(Reperfusion)=F(Xb+ Hospital Effect)
and is estimated using a logit model; see Appendix II. Index refers to the logit index
(XB+Hospital Effect) from this equation. It is demeaned to the average value of patients receiving
reperfusion. Hospital treatment rate refers to the risk-adjusted treatment rate. All models include
all CCP risk-adjusters. Sample-size in every regression is 138,957.




                                                                                                      52
TABLE VI: Sensitivity of the Effect of Reperfusion on 30-day Survival to Controls, Logit Estimates
                                  (1)             (2)              (3)                  (4)

Reperfusion                          0.424         0.192                 0.207                0.199
                                    (0.020)       (0.021)               (0.025)              (0.026)


Controls:

 Age-sex-race                      No                 Yes                Yes                  Yes

 Full CCP controls                 No                 No                 Yes                  Yes

 Zipcode Characteristics           No                 No                 No                   Yes

 AHA/ACC Criteria                  No                 No                 No                   Yes


Note: Coefficients are log-odds. Sample-size in every regression is 138,957. Age-sex-race were full
interactions between five-year age categories, race categories, and gender categories. Zipcode
characteristics included ln(average income), % with high school diploma, and % with college degree.
Ideal for Cath and reperfusions reflect American Hospital Association and American College of
Cardiology (AHA/ACC) criteria for reperfusion that were created for each patient by expert reviewers
using the CCP data but were not in the information that admitting physicians saw. Ideal patients for a
treatment are those for whom the treatment would almost always be indicated, and less-than-ideal
candidates are patients for whom the therapy would be controversial.




                                                                                                    53
     TABLE VII: Effect of Reperfusion on 30-day Survival, Hierarchical-Logit Estimates


  Reperfusion Equation:
    Std. Dev. Of Hospital Reperfusion Rate (Î¸)                                     0.442
                                                                                  (0.013)
  30-day Survival Equation:
    Reperfusion                                                                    0.265
                                                                                  (0.026)
    Reperfusion * Propensity Index                                                 0.276
                                                                                  (0.018)
    Hospital-level intercept (Î±0; general productivity)
      Standard Deviation                                                           0.199
                                                                                  (0.017)
       Correlation with Hospital Reperfusion Rate (Î¸)                             -0.100
                                                                                  (0.073)
    Hospital minimum treatment threshold (Ï„)
      Standard deviation                                                            0.327
                                                                                   (0.055)
       Correlation with Hospital Reperfusion Rate (Î¸)                              -0.341
                                                                                  -(0.106)
       Correlation with General Productivity (Î±0)                                  -0.321
                                                                                   (0.150)
  Number of Hospitals                                                              4,690
  Control for Propensity Index                                                     Linear


Note: Coefficients are log-odds. Table reports estimates from hierarchical logit, where the propensity
to receive treatment is estimated simultaneously with the survival equation. See Section III.C for
details.




                                                                                                     54
TABLE VIII: Effect of Reperfusion on 30-day Survival, By Type of Hospital

Reperfusion                                                     0.205
                                                               (0.195)
Reperfusion*Propensity Index                                    0.289
                                                              (0.0171)

Reperfusion*Church Operated Hospital                          -0.0119
                                                              (0.0596)

Reperfusion*For-Profit Hospital                                0.0341
                                                              (0.0750)

Reperfusion*Government Hospital                                0.0230
                                                              (0.0719)

Reperfusion*ln (Discharge Volume)                              0.0214
                                                              (0.0429)

Reperfusion*Major Teaching Hospital                            0.0352
                                                              (0.0816)

Reperfusion*Minor Teaching Hospital                           -0.00622
                                                              (0.0675)

Reperfusion*Percent of DSH Patients                            -0.156
                                                               (0.200)

Reperfusion*ln (Beds)                                         0.00949
                                                              (0.0516)

Reperfusion*Resident to Bed Ratio                              -0.230
                                                               (0.296)

Constant                                                       0.0984
                                                              (0.0757)


Propensity                                                       Linear
Hospital Random Effects                                            Yes

Observations                                                   138,957
Number of Hospitals                                              4,690


Note: Coefficients are log-odds, from mixed-logits that allow for random coefficients and
are analogous to Table 4. Omitted characteristics is a non-profit hospital. 30-day survival is
regressed on hospital-characteristics and hospital characteristics interacted with treatment.



                                                                                                 55
The table reports the interaction effects. A test of joint-significance on these interactions
yielded a chi-square statistic of 2.96, p=.097.




                                                                                                56
                         TABLE IV: Minimum Chi-Squared Estimates of Structural Parameters

                                Pooling All Hospitals                  Separately by Hospital Volume
                                Just-        Constrain          Different Reliability      Same Reliability
                              identified        w=r             by Hospital Volume       by Hospital Volume

Std. Dev (Î±0)                    0.198           0.204                 0.200                       0.200
                               (0.0167)         (0.017)               (0.016)                     (0.016)
Std. Dev (Î±Î”)                    0.317           0.407                 0.337                       0.336
                                (0.058)         (0.059)               (0.057)                     (0.057)
Corr(Î±Î”, Î±0)                    -0.390          -0.438                -0.457                      -0.438
                                (0.145)         (0.130)               (0.148)                     (0.154)
Ïƒv                               0.435           0.367                 0.431                       0.441
                                (0.152)         (0.218)               (0.117                      (0.135)
w (weight)                       0.154        constrained              0.119                       0.114
                                (0.169)                               (0.107)                     (0.127)
r (reliability)                  0.065           0.155                                             0.040
                                (0.106)         (0.162)                                           (0.069)
r (big Hospitals)                                                      0.069
                                                                      (0.093)
r(Medium Hospitals)                                                    0.047
                                                                      (0.063)
r(Small Hospitals)                                                     0.019
                                                                      (0.026)

# moments being fit               6               6                      18                         18
Degrees of freedom                0               1                      10                         12
Chi-Squared statistic            NA              10.4                   12.7                       62.4
(p-value)                                      (p=.001)               (p=.24)                    (p<.001)


The first two columns fit 6 reduced-form moments estimated from our empirical model (the variances and
covariances of Î¸, Ï„, and Î±0) as a function of the unknown structural parameters in this framework (the
variance and covariance of Î±Î” and Î±0, the reliability of the signal r, the weight placed on the signal w, and the
scale parameter from the logit Ïƒv). The reduced-form moments were estimated pooling all hospitals. The
unknown structural parameters were estimated using minimum chi-squared methods. The last two columns fit
our model to reduced-form moments estimated separately for low (20 or fewer patients), medium (21-80
patients) and high (81 or more patients) volume hospitals - 6 moments for each group, for a total of 18
moments.




                                                                                                        57
